BRITISH NUCLEAR MEDICINE SOCIETY ANNUAL MEETING

21 - 24 APRIL 2013 Brighton Conference Centre

www.bnms.org.uk

A maximum of 15 CME/CPD credits have been awarded to the meeting

Contents

2 British Nuclear Medicine Society

3 General information

4 Social events

5 At a glance programme

9 Programme Sunday – Boot Camp Day 1 - Monday 22 April Day 2 - Tuesday 23 April Day 3 - Wednesday 24 April

19 Poster Presentations

24 Finding your way to the Brighton Centre

25 Finding your way around Brighton

26 Exhibiting companies and Exhibition plan

27 Exhibiting companies

31 BNMS membership application form

32 Methods of membership payment

41ST ANNUAL MEETING 1 21ST-24TH APRIL 2013 British Nuclear Medicine Society

Scientific Committee Conference organisation Conference registration

Dr J Bomanji (Chair) Scientific Chair Dr J Bomanji On-line Registration only: Ms S Allen Poster Session Organiser Dr P Ryan www.bnms.org.uk Prof A Al-Nahhas Judging Panel Dr J Bomanji Tel: 020 8676 7864 Dr P Arumugam YIP judging: Dr B Neilly, Dr M Hall Fax: 020 8676 8417 Dr A Bolster Email: [email protected] Mrs J Croasdale Exhibition Organiser Mrs S Hatchard Dr R Ganatra Conference Secretariat Mrs S Hatchard Dr G Gnanasegaran Ms C Weston Dr S Hughes Ms N Fenning Dr P Kemp Mr P Maltby Dr C Marshall Society membership Dr P Ryan (Poster Chair) Mr P Facey Membership of the British Nuclear Medicine Mrs S Farrell Society is open to those who have a Ms C Lory substantial interest and involvement in the development and provision of Nuclear Medicine services. The Society exists to 2012/13 Council members further the professional, scientific and clinical interests of members and to support the Dr JB Neilly President development of Nuclear Medicine for the Prof AC Perkins Immediate past-President benefit of patients. Ms S Allen Hon Secretary Prof S Vinjamuri Hon Treasurer Dr J Birchall Trustee Subscription rates Dr G Flux Trustee Dr R Graham Trustee UK Overseas Ms C Greaves Trustee Full Member £132 £172 Dr D Green Trustee Full Member-reduced rate £108 £122 Dr M Hall Trustee Associate Member £60 £87 Mr P Maltby Trustee Dr P Ryan Trustee An application form for membership can be Dr P Arumugam, BNCS President found at the back of the programme. Further Mr P Facey Clinical Practitioner details are available at the Conference Mrs S Farrell Clinical Practitioner Registration Desk or by visiting our web site Dr A Corrigan Medical Trainee (www.bnms.org.uk) Dr J Ballinger NMC News & Views Mr M Ward NM Industry Association Ms C Lory Nurse Mrs H Scicluna Nurse to be apponted Patient Representative Mrs J Croasdale Radiopharmaceutical Sciences Dr J Bomanji Scientific Committee

41ST ANNUAL MEETING 2 21ST-24TH APRIL 2013 General Information

AV Centre and Speaker preview Commercial Exhibition - 1st Floor Pre-registration Registration 1st Floor Monday 09.00 – 17.30pm ‘Meet and Greet’ Reception 08.30 daily. Alternatively pre-register at BNMS stand and Internet access Tuesday 09.00 – 17.30pm Sunday 21 April 5.30 – 7.00pm the ‘Meet and Greet’ Reception on Wednesday 09.00 - 14.00pm Foyer, Brighton Convention Centre. Sunday 5.30 - 7pm. Exhibition Hall - stand No.29

BOOT CAMP - Sunday afternoon Emergency contact details Prizes for proffered papers and posters Special interest groups Our Boot camp this year is covering all aspects of PET-MR to include setting up a The emergency contact telephone number for Young Investigator’s Prize Monday PET-MR service, clinical applications, Do’s and delegates attending the conference is £500 awarded by BNMS. BNMS Clinical Scientists Forum don’ts for Clinical Practitioners and Research. 01273 290 131 Syndicate 1 & 2 13.15 – 13.45 Clinical Practitioner prizes funded by an A fee of £25 for members (£35 non-members) Educational Grant from Covidien BNMS Nurses AGM is being charged to include lunch. A Hotel accommodation 1st Oral £300 Syndicate 3 & 4 13.15 – 13.45 maximum of 3 CME/CPD credits have been 1st Poster £300 awarded to Boot Camp. See hotel listing and booking form on the Tuesday BNMS website www.bnms.org.uk Oral paper prizes awarded by Philips BNMS Medics Forum or contact Reservation Highway: 1st £300 Auditorium 2 13.15 – 13.45 Catering Tel 01423 525 577 2nd £150 3rd £50 SpR Forum Coffee and Tea in Exhibition hall. See detailed Meeting Room 1 programme. Internet access Oral Multimodality prize awarded by Ground Floor 13.15 – 13.45 Hermes £350 Tea and Coffee will be available free of charge Free internet access is available for delegates BNMS Clinical Practitioner AGM in the exhibition area. in the Exhibition Hall on the BNMS stand. Poster prizes awarded by GE Healthcare Syndicate 1 & 2 13.15 – 13.45 1st £300 09.00 – 17.00 Coffee shop 2nd £150 BNMS Radiopharmaceutical Sciences AGM Tea/coffee/soft drinks, crisps and Lanyards 3rd £50 Syndicate 3 & 4 13.15 – 13.45 confectionery. Selection of sandwiches, baguettes, cakes and pastries. Kindly sponsored by Siemens Poster Multimodality prize awarded by 15.30 UK PET Physics Group Wednesday Complimentary Buffet lunch Hermes £250 Radiation Protection in PET – in principle and in practice Pads Radiopharmacy a new prize of £250 for CME/CPD 2013 awarded by IBA Molecular UK BNMS Members’ AGM Kindly sponsored by InHealth Group Auditorium 2 17.15 – 18.00 A maximum of 15 CME/CPD credits have Student Prize been awarded to this meeting. Delegates can 1st £100 and free registration awarded by Wednesday only record the actual number of hours Pens BNMS on abstract submission alone 08.30 Nuclear Medicine Therapy Group attended for CME/CPD purposes. 2nd £75 (Molecular Radiotherapy) Please note: CME/CPD certificates will be Kindly sponsored by Sirtex 3rd £50 Molecular therapy in the UK: toward available for collection at the end of each day evidence-based harmonisation or on Wednesday for those attending all three Poster display and Judging- days of the meeting. Exhibition Hall Monday Posters P1 - P38 also CP1 - CP9 Tuesday Posters P39 - P78

41ST ANNUAL MEETING 3 21ST-24TH APRIL 2013 Social Events

‘Meet & Greet’ Reception BNMS Cocktail Party Charity Fun Run BNMS Awards Ceremony and Dinner

Sunday 21 April 5.30 pm – 7.00 pm Monday 22 April 6.00 pm – 8.00 pm Tuesday 23 April 7.30 am Tuesday 23 April 7.30 pm to midnight Conference Centre Foyer Held in The Restaurant, 3rd Floor, Conference Meet on the Lower Promenade opposite the Regency Ballroom, Hilton Brighton Metropole Centre Brighton Centre Hotel

CHARITY FUN RUN along the sea front - all proceeds going to AUTISM SUSSEX - this is going to be a 3 kilometre run. Donations gratefully accepted. Autism Sussex is an independent, not for profit organisation and registered charity, whose aim is to provide a range of opportunities for children, young people and adults with autistic spectrum conditions and/or Asperger syndrome

41ST ANNUAL MEETING 4 21ST-24TH APRIL 2013 At a glance programme

SUNDAY 21 APRIL AUDITORIUM 2

13.15 BOOT CAMP - PET/MR Complimentary Buffet lunch

14.00 Setting up a PET/MR service

14.20 Basic Principals of MRI: Physics made easy

14.40 MRI Functional imaging (T1, T2, DWI etc): What does it mean?

15.00 Clinical applications of PET/MRI (Cardiac/Vascular)

15.30 Tea

16.00 Clinical applications of PET/MRI (Lymphoma/ Head & neck)

16.20 Clinical Practitioner Viewpoint: Do's and Don’ts to maintain technical quality

16.40 Clinical applications of PET/MRI (Gynae/GIT)

17.00 PET/MR Research Programme

41ST ANNUAL MEETING 5 21ST-24TH APRIL 2013 At a glance programme

MONDAY 22 APRIL AUDITORIUM 2 MONDAY 22 APRIL SYNDICATE 1 & 2 MONDAY 22 APRIL SYNDICATE 3 & 4

09.00 INAUGURATION BONE CLINICAL PRACTITIONERS CONTINUING EDUCATION 09.10 IMAGING THE SPINE: WHEN TO SPECT-CT, PET-CT OR PET-MRI ENDOCRINE AND MISCELLANEOUS SESSION I: PET-CT 09.30 IMAGING BONE METASTASES: SPECT & PET TRACERS 09.15 Proffered papers 09.15 WALES RESEARCH AND DIAGNOSTIC POSITRON EMISSION TOMOGRAPHY IMAGING CENTRE - THE STORY SO FAR 09.50 RADIONUCLIDE IMAGING IN SPORTS INJURIES 09.45 THE FIRST TWO YEARS OF PET-CT – OUR CLINICAL EXPERIENCE 10.10 DO'S & DON’TS TO MAINTAIN HIGH QUALITY IMAGING: CLINICAL PRACTITIONER'S VIEW 10.15 PET-CT IN LUNG CANCER– EVERYTHING YOU NEED TO KNOW 10.30 TECHNICAL ADVANCES IN BONE IMAGING: EMPHASIS ON RESOLUTION RECOVERY 10.45 COFFEE and Meet Industry in the Exhibition Hall 10.50 PANEL DISCUSSION CLINICAL PRACTITIONERS CONTINUING EDUCATION 11.00 COFFEE and Meet Industry in the Exhibition Hall 11.00 COFFEE and Meet Industry in the SESSION II: THERAPY Exhibition Hall BRAIN 11.15 RADIOTHERAPY PLANNING IN PET-CT - FIRST CONTACT

11.30 SPECT & PET IN EPILEPSY 11.30 BONE AND LUNG 177 Proffered papers 11.45 Lu DOTATE THERAPY – OUR EXPERIENCE 11.50 PET-CT IN ADDICTION 12.15 NUCLEAR MEDICINE MOVES INTO INTERVENTION RADIOLOGY - THE 12.10 ADVANCES IN BRAIN PET & SPECT IMAGING: EMPHASIS ON DEMENTIA ROLE OF THE CLINICAL PRACTITIONER IN SELECTIVE INTERNAL RADIATION THERAPY (SIRT) 12.30 TECHNICAL ADVANCES IN BRAIN IMAGING-SOFTWARE 12.30 TECHNICAL ADVANCES IN BRAIN IMAGING-SOFTWARE 12.50 PANEL DISCUSSION 12.45 LUNCH , Poster Session & Meet Industry 13.00 LUNCH , Poster Session & Meet Industry 13.00 LUNCH , Poster Session & Meet Industry PHYSICS I NUCLEAR MEDICINE IN EUROPE & ASIA PACIFIC NEEDLE SAFE WORKSHOP 14.00 ROLE OF PET-CT IN ESTABLISHED AND EMERGING CLINICAL 14.00 Proffered papers 14.00 The Health & Safety (Sharp Instruments in Healthcare) Regulations 2013 APPLICATIONS: THE DANISH EXPERIENCE 14.15 INDUSTRY DEMONSTRATIONS 14.30 ROLE OF NUCLEAR MEDICINE IN IMAGE-GUIDED SURGERY TODAY AND PERSPECTIVES AHEAD 15.00 AFFORDABLE NUCLEAR MEDICINE: NEW TRACERS FROM INDIA 15.00 TEA and Meet Industry in the Exhibition Hall 15.30 TEA and Meet Industry in the Exhibition Hall 15.30 NUCLEAR MEDICINE IN MIDDLE EAST 15.30 NEUROLOGY Proffered papers GENERAL NUCLEAR MEDICINE 1 16.00 PANEL DISCUSSION 16.00 SeHCAT: NICE GUIDELINES, AND FUTURE 16.10 TEA and Meet Industry in the Exhibition Hall 16.20 CHANGING LANDSCAPE IN PAEDIATRIC IMAGING 16.40 HOMEWORK FOR WRITING A BUSINESS PLAN: SPECT/CT SERVICE 16.30 ENDOCRINE & EDUCATION THE SCIENCE AND TECHNOLOGY FACILITIES COUNCIL AND NUCLEAR MEDICINE 17.00 ROLE OF RADIONUCLIDE IMAGING IN THYROID & PARATHYROID SURGERY 17.00 BUSINESS PLAN FOR A PET-CT SERVICE 17.20 ROLE OF PET-CT IN CONGENITAL HYPERINSULISM 17.20 V/Q SPECT 17.40 PANEL DISCUSSION 17.40 PANEL DISCUSSION

18.00 COCKTAIL RECEPTION, The Restaurant, 3rd Floor AGMs/Special interest group forums: lunch time meetings 13.15 BNMS Clinical Scientists Forum - Syndicate 1& 2 13.15 BNMS Nurses AGM - Syndicate 3 & 4

41ST ANNUAL MEETING 6 21ST-24TH APRIL 2013 At a glance programme

TUESDAY 23 APRIL AUDITORIUM 2 TUESDAY 23 APRIL SYNDICATE 1 & 2 TUESDAY 23 APRIL SYNDICATE 3 & 4

CARDIOLOGY I CLINICAL PRACTITIONERS RADIOPHARMACY I 09.00 IMPACT OF NICE GUIDELINES ON MPS IMAGING 09.00 Proffered Papers 09.00 UPDATE ON NEW NON-PET TRACERS COMING TO MARKET

09.30 MPS MORPHING WITH COMPETING MODALITIES 09.30 UPDATE ON NEW PET TRACERS COMING TO MARKET

09.50 EMERGING APPLICATIONS: FOCUS ON SARCOIDOSIS & AMYLODOSIS 10.00 RESURRECTING THE POWER OF RADIOCHEMISTRY FOR 10.10 TECHNICAL ADVANCES: NEW CAMERAS & SOFTWARE FOR MYOCARDIAL MOLECULAR IMAGING PERFUSION & FUNCTION

10.30 DO'S & DON’TS TO MAINTAIN HIGH QUALITY IMAGING: CLINICAL 10.30 THE ROLE OF THE IAEA IN FOSTERING USE OF PRACTITIONER'S VIEW RADIOPHARMACEUTICALS 10.45 COFFEE and Meet Industry in the 10.50 PANEL DISCUSSION Exhibition Hall CARDIOLOGY II 11.00 COFFEE and Meet Industry in the Exhibition Hall 11.00 Proffered Papers 11.00 COFFEE and Meet Industry in the Exhibition Hall

ONCOLOGY 1 RADIOPHARMACY II 11.30 PET-CT: WHERE ARE WE IN CURRENT GUIDELINESS IN CANCER IMAGING? 11.30 Proffered Papers

11.50 PET-CT IN GYNAECOLOGICAL MALIGNANCY

12.10 PET-CT/MRI IN PROSTATE CANCER 12.15 UPDATE ON THE MOLYBDENUM SUPPLY SITUATION AND PET 12.30 PET-CT IN PARANEOPLASTIC SYNDROME REVIEW OF RADIOPHARMACEUTICAL SERVICES

12.50 PANEL DISCUSSION

13.00 Lunch and Meet Industry 13.00 Lunch and Meet Industry 13.00 Update on Clinical Pharmaceutical Sciences STP course as part of Modernising Scientific Careers

13.15 Lunch and Meet Industry

14.00 ANNUAL LECTURE: ADVANCES IN HIGH RESOLUTION MULTI-MODALTIY IMAGING: FROM PHYSICIST TO PHYSICIAN

15.00 TEA, poster viewing & meet industry 15.00 TEA, poster viewing & meet industry YOUNG INVESTIGATOR PRIZE ONCOLOGY II 15.30 Proffered Papers 17.15 BNMS Annual General Meeting 15.45 Proffered Papers (Auditorium 2)

AGMs/Special interest group forums: lunch time meetings 13.15 BNMS Clinical Practitioners AGM - Syndicate 1 & 2 13.15 Medics Forum - Auditorium 2 13.15 SpR Forum - Meeting Room 1, Ground Floor 13.15 BNMS Radiopharmaceutical Sciences Group AGM - Syndicate 3 & 4 15.30 UK PET Physics Group – Auditorium 2

41ST ANNUAL MEETING 7 21ST-24TH APRIL 2013 At a glance programme

WEDNESDAY 24 APRIL AUDITORIUM 2 WEDNESDAY 24 APRIL SYNDICATE 1 & 2 WEDNESDAY 24 APRIL SYNDICATE 3 & 4

GENERAL NUCLEAR MEDICINE II 08.30 Nuclear Medicine Therapy Group (Molecular Radiotherapy) 08.00 CHANGING LANDSCAPE FOR NUCLEAR MEDICINE TRAINEES: PREPARE ONCOLOGY III SPECIAL INTEREST GROUP YOURSELF Molecular radiotherapy in the UK: Toward evidence-based 08.45 Proffered Papers harmonisatio n 08.50 THE NEXT GENERATION OF MEDICS: GUIDANCE FROM THE BNMS PRESIDENT

09.10 SENTINEL NODE IMAGING: CURRENT STATUS & FUTURE DIRECTIONS

09.30 LIVER TRANSPLANT IMAGING

09.50 PANEL DISCUSSION

10.00 COFFEE and Meet Industry in the Exhibition Hall 10.00 COFFEE and Meet Industry in the Exhibition Hall PHYSICS II ONCOLOGY II ONCOLOGY IV 10.00 Proffered Papers 10.30 CURRENT PRACTICE & CONTROVERSIES IN RADIONUCLIDE THERAPY FOR 10.30 Proffered Papers NETS 10.45 COFFEE and Meet Industry in the Exhibition Hall 10.50 SELECTION & FOLLOW UP OF PATIENTS WITH NETS

11.10 CURRENT PRACTICE & CONTROVERSIES IN RADIONUCLIDE THERAPY FOR DTC

11.30 MANAGEMENT STATERGY IN IODINE-NEGATIVE/THYROGLOBULIN-POSITIVE PATIENTS

11.50 DO'S & DON’TS TO MAINTAIN A HIGH QUALITY THERAPY UNIT-PHYSICISTS VIEW

12.15 PRIZE PRESENTATION (Auditorium 2)

12.30 HIGHLIGHTS LECTURE (Auditorium 2)

13.15 COMPLIMENTARY LUNCH AND CLOSE OF MEETING

41ST ANNUAL MEETING 8 21ST-24TH APRIL 2013 Programme

SUNDAY 21 AUDITORIUM 2 MONDAY 22 AUDITORIUM 2

BOOT CAMP 17.00 PET-MR Research programme 09.00 Inauguration 11.00 COFFEE and Meet Industry in the 13.15 Complimentary buffet lunch Prof Ashley Groves Dr Brian Neilly – BNMS President and Exhibition Hall Institute of Nuclear Medicine, UCLH Prof Alan Perkins, Immediate Past 14.00 Setting up a PET-MR Service President BRAIN Dr Jamshed Bomanji 17.30 'Meet and Greet' reception - Foyer Chairs: Dr Kevin Bradley, Institute of Nuclear Medicine, UCLH approval applied for BONE Dr Simon Hughes Chairs: Dr Paul Ryan, 14.20 Basic principals of MRI: Physics Separate CME credits have Dr Gopinath Gnanasegaran 11.30 SPECT and PET in Epilepsy made easy been applied for Boot Camp. Dr Beate Dielh Mr Peter Lally 09.10 Imaging the Spine: When to Institute of Neurology, University Institute of Nuclear Medicine, UCLH SPECT/CT, PET-CT or PET/MRI College London Dr Rizwan Syed 14.40 MRI Function Imaging (T1, T2, DWI Institute of Nuclear Medicine, UCLH 11.50 PET-CT in Addiction etc.): What does it mean? Dr Jeff W Dalley Dr Shonit Punwani 09.30 Imaging Bone Metastases: SPECT Department of Psychology, University University College Hospital, London and PET Tracers of Cambridge Prof Gary Cook 15.00 Clinical applications of PET-MRI King’s College London 12.10 Advances in brain PET and SPECT (Cardiac/Vascular) imaging: Emphasis on dementia Dr Leon Menezes 09.50 Radionuclide Imaging in Sports Prof Peter J Ell Institute of Nuclear Medicine, UCLH Injuries Institute of Nuclear Medicine, London Dr Ranju Dhawan 15.30 Tea Imperial College Healthcare NHS 12.30 Technical advances in brain Trust imaging: Software 16.00 Clinical applications of PET-MRI Dr John Dickson (Lymphoma/Head & Neck 10.10 Do’s and Don’ts to maintain high Institute of Nuclear Medicine, London Dr Irfan Kayani quality imaging: Clinical Institute of Nuclear Medicine, UCLH Practitioner’s View 13.00 LUNCH, Poster Session and Meet Mrs Ann French Industry in the Exhibition Hall 16.20 Clinical Practitioner viewpoint: Glasgow Royal Infirmary Do’s and Don’ts to maintain NUCLEAR MEDICINE IN EUROPE technical Quality 10.30 Technical advances in bone AND ASIA PACIFIC Celia O’Meara imaging: Emphasis on resolution Chairs: Dr Jamshed Bomanji Institute of Nuclear Medicine, UCLH recovery Mr Steve Ebdon-Jackson Dr Matt Aldridge, 16.40 Clinical applications of PET-MRI Institute of Nuclear Medicine, London 14.00 Role of PET-CT in established and (Gynae/GIT) emerging clinical applications: The Danish experience Dr Rizwan Syed 10.50 PANEL DISCUSSION Institute of Nuclear Medicine, UCLH Dr Vineet Prakash Ashford & St Peter’s NHS Trust

41ST ANNUAL MEETING 9 21ST-24TH APRIL 2013 Programme

MONDAY 22 SYNDICATE 1 & 2

14.30 Role of Nuclear Medicine in 17.20 Role of PET-CT in Congenital ENDOCRINE & MISCELLANEOUS R Sharma, A Al-Nahhas image-guided surgery today and Hyperinsulism Chairs: Dr Richard Graham, Imperial College Healthcare NHS perspectives ahead Dr Khalid Hussain Dr Francis Sundram Trust, London, UK

Prof Markus Schwaiger UCL Institute of Child Health and 68 Technical University of Munich, Great Ormond Street Hospital for 09.15 1. Somatostatin Peptide Receptor 10.15 5. Role of Ga-DOTATATE PET-CT Germany Children Radionuclide Therapy (PRRT) with in patients with suspected or 177 Lu-DOTATATE for recurrent known Neuroendocrine Tumors 15.00 Affordable Nuclear Medicine: New 17.40 PANEL DISCUSSION meningioma and pituitary (paper no. 1 in NMC) tracers from India adenoma (paper no. 5 in NMC) E Panagiotidis, M Al Harbi, Dr B A Krishna 18.00 COCKTAIL RECEPTION MD Aldridge 1, J Maclean 2, A Haroon 1, K Al-Nabhani, R Sajjan, Z Saad, Bombay Hospital, Mumbai, India The Restaurant, 3rd Floor N Fersht 2, TA Soderlund 1, D Neriman, M. Caplin, J Bomanji WA Waddington 1, J Bomanji 1 Institute of Nuclear Medicine, UCL, 15.30 Nuclear Medicine in the Middle 1Institute of Nuclear Medicine, London, UK East London 2 10.30 6. Circulating granulocyte survival Dr A. Almuhaideb Dept of Oncology, UCLH, London, UK is reduced in inactive alcohol- King Faisal Specialist Hospital and related cirrhosis Research Center, Saudi Arabia 09.30 2. Is 99m Tc-MIBI JR Potts 1, N Farahi 2, ER Chilvers 2, 99 3 1 1 16.00 PANEL DISCUSSION methoxyisobutylisonitril ( mTc- S Heard , S Verma , AM Peters MIBI) tissue elimination influenced 1Department of Medicine, Brighton by variation in the MDR1 gene? and Sussex Medical School, 16.10 TEA and Meet Industry in the 2 Exhibition Hall S Dizdarevic 1, M Aplin 1, MJ Newport 1, Department of Medicine, University 1 1 1 of Cambridge, N Ryan , SG Holt , S Goubet , 3 ENDOCRINE AND EDUCATION L Goldberg 1, KA Miles 2 AM Peters 1 Department of Nuclear Medicine, 1Brighton and Sussex University Cambridge University Hospitals NHS Chairs: Dr Brian Neilly Foundation Trust, UK Dr Andrew Scarsbrook Hospitals NHS Trust and Brighton and Sussex Medical School 2 10.45 7. Influence of enterohepatic 16.30 The Science and Technology Institute of Nuclear Medicine, UCL, London, UK bile acid recycling rate on whole Facilities Council and Nuclear body 75 Se-HCAT retention Medicine 09.45 3. Limiting Acute Nephrotoxicity in AM Peters 1, JRF Walters 2 Dr Barbara Camanzi Patients Undergoing Peptide 1Brighton Sussex Medical School, STFC Cancer Care Strategy Leader Receptor Radionuclide Therapy 2Imperial College, London, UK (PRRT) Flow using 82 Rb-PET 17.00 Role of Radionuclide imaging in 11.00 COFFEE and Meet Industry in the Thyroid and Parathyroid Surgery P Maltby, M Trabelsi, G McKane, S Vinjamuri Exhibition Hall Mr Tom Kurzawinsky Royal Liverpool & Broadgreen University College Hospital, London University Hospitals NHS Trust, UK BONE and LUNG Chairs: Dr Mohan Hosahalli, 10.00 4. Use of 68 Ga-DOTATATE in Dr Brent Drake, paragangliomas Dr Rijju Gopinath H Tam, A Boles, L Perry, A Frilling,

41ST ANNUAL MEETING 1 0 21ST-24TH APRIL 2013 Programme

11.30 8. Making the most of technology 12.30 12. Validation of simultaneous 14.15 15. Implementing a system for Castillo-Matos, N. Martínez-Amador, to improve throughput in bone 81m Kr 99m Tc dual isotope receiving 15 O gas in a PET J.M Carril scanning SPECT V/Q Acquisition scanner room Marqués de Valdecilla University I Armstrong, D Tout, G Al-Bahrani, A Neale, A Notghi, K Alam, N Bird, G Whish, S Yates Hospital, University of Cantabria, E Johnstone, J James W Thomson Addenbrooke's Hospital, Cambridge, Santander, Spain Central Manchester University Sandwell and West Birmingham UK Hospitals, UK Hospital, UK 15.45 19. An assessment of the role of 14.30 16. Predicting the optimal number FDG PET in the decision making 11.45 9. Incremental value of 18 F- 12.45 13. Planar images reprojected from of Eigenimages to be used in a for Epilepsy Surgery Choline-PET-CT in detection and SPECT V/Q data perform similarly diagnostic normal brain atlas JC Dickson 1, C Rathore 2, PJ Ell 1, 2 characterization of skeletal to traditional planar V/Q scans in 1 2 JS Duncan C H Bjuren , S D Bloomer , 1 findings in suspected biochemical the diagnosis of pulmonary A S Houston 1 Institute of Nuclear Medicine, relapse: First UK experience embolism 1 University College London Hospital, University of Stirling, 2 A Haroon, J Afgan, R Allie, P Kyrtatos, S Navalkissoor, 2Hermes Medical Solutions, London, Department of Clinical and R Endozo, M Emberton, J Bomanji M Burniston, F Wickham, T Wagner UK Experimental Epilepsy, National University College London Hospital Nuclear Medicine Department, Royal Hospital for Neurology and NHS Trust, UK Free London NHS FT, UK 14.45 17. Is Monte Carlo Scatter Neurosurgery, London, UK Correction (MCSC) of 123 I without 12.00 10. Painful Knee Prosthesis: Can 13.00 LUNCH, Poster Session and Meet collimator response modelling 16.00 20. Evaluation of the clinical We Help with SPECT/CT? Industry sufficient for studies acquired with effectiveness of FDG-PET-CT in the diagnosis of early dementia K Al-Nabhani, J Alkalbani, LEHR collimators? S Michopoulou, R Syed, J Bomanji 13.15 BNMS Clinical Scientists Forum CM Brown 2, G Gillen 1, J Prosser 1, E Cunningham, P Fearon, Institute of Nuclear Medicine, PHYSICS I MF Dempsey 1 P Passmore, D Craig, S Todd, University College London Hospital, 1Gartnavel General Hospital, S Hughes Chairs: Dr Chris Marshall Belfast HSC Trust, UK UK Dr Lefteris Livieratos Glasgow, 2University of Glasgow, UK 16.15 21. Quantitative assessment of the 12.15 11. Pelvic bone marrow 14.00 14. Design, execution and testing involvement in metastatic prostatic 15.00 TEA and Meet Industry in the reproducibility of specific binding of a phantom to allow optimisation ratio in full and reduced activity cancer – the role of isotope bone of simultaneous dual isotope Exhibition Hall scan pre-synaptic dopamine transporter Krypton SPECT V/Q imaging imaging with [ 123 I]-FP-CIT 1 2 2 NEUROLOGY M JafariI , E Jefferson , A Mackie , 1 2 1 3 CD Baker, JCM Fowler SA Smith , J Prosser , J Robinson , I Minty 1 Chairs: Dr Sabina Dizdarevic, 3 3 1 1 Royal Brompton and Harefield NHS CA Paterson , G Dewar , W Martin James Cook University Hospital, Dr Gregory Shabo, Dr Vinnet Prakash 1 2 Foundation Trust, Nuclear Cardiology, Glasgow Royal Regional Medical Physics 2East and North Hertfordshire NHS Department, County Durham and 15.30 18. Visual and Semi-quantitative Infirmary, Trust, UK 2 Darlington NHS Foundation Trust, assessment of [ 11 C]PIB PET-CT Nuclear Medicine, Gartnavel General 3 Hospital, Glasgow, Radiology Department, County in patients with cognitive 3 Durham and Darlington NHS impairment Nuclear Medicine, Royal Hospital, Larbert, UK Foundation Trust, UK F. Ortega-Nava, J. Jiménez-Bonilla, I. Banzo, I. Martínez-Rodríguez, E. Rodríguez, I. Mateo, R. Del

41ST ANNUAL MEETING 1 1 21ST-24TH APRIL 2013 Programme

MONDAY 22 SYNDICATE 3 & 4

16.30 22. Effect of transverse tilt on CLINICAL PRACTITIONERS 12.15 Nuclear Medicine moves into 16.00 SeHCAT: NICE Guidelines and quantification in [ 123 I]-FP-CIT CONTINUING EDUCATION Intervention Radiology – The Role Future SPECT SESSION 1: PET-CT of the Clinical Practitioner in Dr Annelies Maenhout M Burniston, P Kyrtatos, T Wagner, Chairs: Sally Farrell, Sandra Johns Selective Internal Radiation Chelsea and Westminster Hospital F Wickham Therapy (SIRT) Royal Free NHS Foundation Trust, 09.15 Wales Research and Diagnostic Sandra Johns 16.20 Changing Landscape in Paediatric London, UK Positron Emission Tomography University Hospital Southampton Imaging Imaging Centre – The Story so far Dr Tom Lynch, 16.45 23. What is the impact of MR Phil Facey 12.45 LUNCH, Poster Session and Meet Belfast City Hospital, based attenuation correction on University Hospital of Wales Industry standard and quantitative 16.40 Planning for SPECT/CT before and neurological PET/MR? 09.45 The First Two Years of PET-CT – 13.15 Nurses AGM after installation JC Dickson, A Barnes, C O'Meara, Our Clinical Experience NEEDLE SAFE WORKSHOP Danny McCool LJ Menezes Chris O’Callaghan, Royal Free Hospital Institute of Nuclear Medicine, University Hospital of Wales Chair: Carolyn Lory University College London Hospital, 17.00 Business Plan for a PET-CT UK 10.15 PET-CT in Lung Cancer – 14.00 The Health and Safety (Sharp Service Everything you need to know Instruments in Healthcare) 18.00 COCKTAIL RECEPTION Regulations 2013 Dr Simon Hughes The Restaurant, 3rd Floor Dr Patrick Fielding Nottingham City Hospital University Hospital of Wales Anne Bartlett Hazardous Installations Directorate, 17.20 V/Q SPECT Health & Safety Executive 10.45 COFFEE and Meet Industry in the Dr Alp Notghi Exhibition Hall 14.15 INDUSTRY DEMONSTRATIONS Birmingham City Hospital CLINICAL PRACTITIONERS Bright Technologies 17.40 PANEL DISCUSSION CONTINUING EDUCATION Stephen Anderson SESSION II: THERAPY Fannin 18.00 COCKTAIL RECEPTION Chairs: Phil Facey Louise Coles The Restaurant, 3rd Floor Terumo 11.15 Radiotherapy planning in PET-CT – David Dixon First Contact Chris O’Callaghan 15.30 TEA and Meet Industry in the University Hospital of Wales Exhibition Hall

11.45 177 Lu Dotate Therapy – Our GENERAL NUCLEAR MEDICINE I Experience Chairs: Dr Robert Reid, Sally Farrell Prof Alan Perkins Derriford Hospital, Plymouth

41ST ANNUAL MEETING 1 2 21ST-24TH APRIL 2013 Programme

TUESDAY 23 AUDITORIUM 2 TUESDAY 23 SYNDICATE 1 & 2

CARDIOLOGY I ONCOLOGY I Advances in High Resolution CLINICAL PRACTITIONERS Chairs: Dr Parthiban Arumugam, Chairs: Dr Wai-Lup Wong Multi-Modality Imaging: from Chairs: Sandra Johns, Lloyd Rowling Prof Richard Underwood Dr Alexis Corrigan Physicist to Physician Professor David Townsend 09.00 24. Brain imaging (SPECT) 09.00 Impact of NICE Guidelines on MPS 11.30 PET-CT: Where are we in current PET and SPECT Development vascular perfusion deficits and Imaging guidelines in cancer imaging Group, Singapore Bioimaging survival in late onset dementia: a Prof Richard Underwood Dr Sally Barrington Consortium longitudinal observational study Imperial College London (National Guy’s & St Thomas’ NHS Trust 15.00 TEA, POSTER VIEWING and Meet L Lambley 1, A Murray 2, L Whalley 2, Heart and Lung Institute) Industry L Lovell 1, R Staff 1 11.50 PET-CT in Gynaecological 1Aberdeen Royal Infirmary, 09.30 MPS Morphing with Competing Malignancy 15.30 UK PET Physics Group 2Aberdeen University, UK Modalities Radiation Protection in PET – Dr Tara Barwick in principle and in practice Dr Nikant Sabharwal Charing Cross Hospital 09.15 25. The added benefit of quantitative MBF to standard 82 Rb Oxford Heart Centre. John Radcliffe 17.15 BNMS ANNUAL GENERAL Hospital 12.10 PET-CT/MRI in Prostate Cancer PET MPI and the correspondence MEETING to anatomical changes Dr Athar Haroon 09.50 Emerging Applications: Focus on Institute of Nuclear Medicine, UCLH M Meintjes, R Endozo, J Dickson, Sarcoidosis and Amylodosis L Menezes, J Bomanji Dr Leon Menezes 12.30 PET-CT in Paraneoplastic University College London Hospital, Institute of Nuclear Medicine, UCLH Syndrome UK Dr Sai Han 09.30 26. Gastric Emptying Studies, an 10.10 Technical Advances: New cameras Glasgow Royal Infirmary and software for Myocardial audit of methodology Perfusion and Function 12.50 PANEL DISCUSSION A French Prof Brian Hutton Glasgow Royal Infirmary,UK Institute of Nuclear Medicine UCLH 13.00 LUNCH and Meet Industry in the Exhibition Hall 09.45 27. An introduction to Magnetic 10.30 Do’s and Don’ts to maintain high Resonance (MR) artefacts for quality imaging: Clinical 13.15 Medics Forum Nuclear Medicine technologists – Practitioners’ View A brief introduction to their causes and how to resolve them Carl Grimsditch 13.15 SpR Forum, Meeting Room 1 Central Manchester University C O'Meara, S Burns, A Barnes, Hospitals NHS Foundation Trust 14.00 ANNUAL LECTURE R Syed, L Menezes, J Bomanji Chairs: Dr Brian Neilly, University College London Hospital, 10.50 PANEL DISCUSSION Prof Alan Perkins UK

11.00 COFFEE and Meet Industry in the Exhibition Hall

41ST ANNUAL MEETING 1 3 21ST-24TH APRIL 2013 Programme

10.00 28. Operator variability in the 11.00 31. A comparison between supine 11.45 34. A Quantitative Comparison of 12.30 37. Advanced reconstruction does analysis of multi gated acquisition and seated myocardial perfusion Planar vs. SPECT MUGA not change coronary flow reserve 82 (MUGA) data to assess left imaging with attenuation G James 1, A Jennings 2, A Notghi 1, estimation in dynamic Rb ventricular ejection fraction correction WH Thomson 1, J O'Brien 1 cardiac PET A Nunes, M Luqman, Y Bouchareb, D Tout, C Tonge, J Adams, P Austin, 1City Hospital, Birmingham, IS Armstrong, CM Tonge, H Jan, E Joel, N Macalintal, A Nacpil, K Colligan, P Arumugam 2University Hospitals Coventry and P Arumugam V Paldo, N Swadling, L Tria-Sajul Central Manchester University Warwickshire, UK Central Manchester University Barts Health NHS Trust, London, UK Hospitals NHS Foundation Trust, UK Hospitals, UK 12.00 35. LVEF Determination using IQ- 10.15 29. Do DMSA defects evident 11.15 32. Characterization Of The SPECT and conventional SPECT: 13.00 LUNCH and Meet Industry between 3 and 6 months post UTI Mineral Deposition And The comparison with Cardiac MRI represent scarring? Inflammatory Metabolism Of The N Bebbington, C Boivin, 13.15 BNMS Clinical Practitioners’ AGM Carotid Atheroma By 18 F-Fluoride D Wright, E Jefferson, A Mackie 18 E Lanchbury, M Wilson, R Steeds University Hospital of North Durham, And F-FDG PET-CT The Queen Elizabeth Hospital ONCOLOGY II UK R Quirce, A Rubio-Vassallo, Birmingham, UK Chairs: Dr Thomas Wagner JF Jiménez-Bonilla, Dr Rakesh Kumar, Dr Zarni Win 10.30 30. Evaluating role of 99m Tc I Martínez-Rodríguez, I Banzo, 12.15 36. Association of Transient Pertechnetate and Dynamic 99m Tc M Rebollo Alvarez-Amandi, ischemic dilation (TID) ratio with 15.45 38. Impact of 18 F-FDG PET-CT in MIBI imaging coupled with MA Revilla García, EJ Palacio Portilla, severity and extent of Coronary suspected or confirmed early SPECT/CT scan for localisation of M De Arcocha-Torres, artery disease (CAD) as assessed stage non-small cell lung cancer 99m Parathyroid adenoma F Ortega-Nava, N Martínez-Amador, by Dipyidamole Tc x 2 Tracer D Colville 1, S Han 1, FW Poon 1, A Nunes, A Haroon, M Luqman, JM Carril Myocardial Perfusion SPECT JB Neilly 2 Marqués de Valdecilla University (MPS): Comparison with Exercise 1 L Childs, A Hameeddudin, 99m Beatson West of Scotland Cancer I Goddard, L Biassoni, T Szyszko, Hospital. University of Cantabria, Tc x 2 Tracers MPS Centre, Glasgow H Jan Santander.Spain K Niyaz 2, F Panwhar 1, J Iqbal 3, 2Glasgow Royal Infirmary, UK Barts Health NHS Trust, London, UK S Habib 3, M Naman 2 11.30 33. Are One Compartment and 1Nuclear Institute of Medicine and 16.00 39. Response and Survival in 10.45 COFFEE and Meet Industry in the Retention models comparable for Radiotherapy (NIMRA), Jamshoro, Oesophageal Cancer Patients the quantification of Myocardial Exhibition Hall 82 Pakistan, Following Neoadjuvant Blood Flow using Rb? 2Fujairah Hospital, Fujairah, United Chemotherapy Assessed by FDG- CARDIOLOGY II JC Dickson, M Meintjes, Arab Emirates, PET-CT and Correlation to 3 Chairs: Dr Liz Prvulovich, LJ Menezes, AM Groves Karachi Institute of Radiotherapy and Pathological Response Dr Kshama Wechelekar, Institute of Nuclear Medicine, Nuclear Medicine (KIRAN), Karachi, S Hughes, Y Manikyam, C Harrison, Dr Nikant Sabharwal University College London Hospital, Pakistan D McManus, C Boyd, PA Carey, UK JA Kennedy, K McManus, M Eatock Belfast HSC Trust, UK

41ST ANNUAL MEETING 1 4 21ST-24TH APRIL 2013 Programme

TUESDAY 23 SYNDICATE 3 & 4

16.15 40. The value of PET-CT in 17.00 43. Contrasting relations with RADIOPHARMACY I 11.45 47. A HEPES free formulation for predicting patient outcome blood glucose level of FDG Chairs: Paul Maltby, Bev Ellis tropolone and its clinical validation following radical treatment of head accumulation in the brain and liver: for use in white cell labelling with 111 and neck cancers potential clinical impact 09.00 Update on new Non-PET Tracers In-Indium chloride LJ Gorf, S Ramkumar, F Sundram G. Keramida 1, J. Shur 2, coming to Market K Solanki, A Wong, W Oware, University Hospital Southampton S. Dizdarevic 2, J. Bush 1, A.M Peters 1 C Solanki 1 Dr Jim Ballinger NHS Foundation Trust, UK Clinical Imaging Science Centre, Guy’s & St Thomas’ NHS Addenbrookes Hospital, Cambridge, Brighton, FoundationTrust UK 16.30 41. Uptake of 11 C Choline, 18 F 2Brighton and Sussex University 18 Methyl Choline and F Ethyl Hospitals, UK 09.30 Update on New PET Tracers 12.00 48. Towards more specific imaging Choline: Physiological distribution, coming to Market of bacterial infection using a statistical differences and 17.15 44. Value Of Baseline 18 F-FDG 18 F-FDG derivative Prof Eric Aboagye imaging pearls PET Quantitative Imaging B Mills 3, RO Awais 2, JCA Luckett 3, 1 2 2 Parameters For Predicting Department of Surgery and Cancer, 4 2 3 A Haroon , L Zanoni , M Celli , Imperial College D Turton , AC Perkins , P Williams , R Zakavi 3, M Beheshti 4, Treatment Response in Hodgkin’s P Hill 1 4 2 1 Lymphoma 1 W Langsteger , S Fanti , J Bomanji 10.00 Resurrecting the power of School of Biosciences, University of 1University College London Hospital B Taylor 1, M Siddique 1, S Barrington 2, Nottingham, 2 1 Radiochemistry for Molecular 2 NHS Trust, NG Mikhaeel , G Cook Imaging Radiological and Imaging Sciences, 2University Hospital Sant'Orsola 1King's College London, University of Nottingham, Malpighi, Bologna, Italy, 2Guy's & St Thomas' NHS Dr Erik Arstad 3School of Molecular Medical 3Mashad University of Medical Foundation Trust, UK University College London Sciences, University of Nottingham, Sciences Iran, 4PETNET Solutions, Nottingham City 4St. Vincent ’s Hospital, Austria 17.30 45. Simultaneous PET/MRI vs 10.30 The Role of IAEA in fostering use Hospital, UK PET-CT in Oncological Patients: of Radiopharmaceuticals 16.45 42. Aortic 18 F-FDG PET-CT uptake measured exuberance Mr Uday Bhonsle 12.15 Update on the Molybdenum pattern at 60’ (early) and 180’ K Al-Nabhani, R Syed, J Alkalbani, International Atomic Energy Agency, Supply Situation and PET (delayed) acquisitions in a control A Afaq, A Barnes, C O'Meara, Austria Review of Radiopharmaceutical population: Semiquantitative R Allie, Z Saad, E panagiotidis, Services comparative analysis R Sajjan, J Bomanji 11.00 COFFEE and Meet Industry in the Prof Alan Perkins I Martínez-Rodríguez, Institute of Nuclear Medicine, Exhibition Hall Queen’s Medical Centre, Nottingham R Del Castillo- Matos, R Quirce, London, UK I Banzo, J Jiménez-Bonilla, RADIOPHARMACY II 13.00 Update on Clinical Pharmaceutical A Rubio-Vassallo, F Ortega-Nava, Chairs: Jilly Croasdale, Bev Ellis Sciences STP course as part of JM Carril Modernising Scientific Careers Marqués de Valdecilla University 11.30 46. Routine preparation of 90 Y, Dr Bev Ellis, Hospital. University of Cantabria, 177 Lu, and 111 In-DOTATATE for Manchester Royal Infirmary Santander, Spain treatment of neuroendocrine tumours 13.15 LUNCH and Meet Industry J Ballinger, Y Tan, S Allen, V Lewington Guy's and St Thomas' NHS Foundation Trust, London, UK

41ST ANNUAL MEETING 1 5 21ST-24TH APRIL 2013 Programme

WEDNESDAY 24 AUDITORIUM 2

13.15 BNMS Radiopharmaceutical 16.30 52. Axillary surgery has no acute GENERAL NUCLEAR MEDICINE II 10.50 Selection and follow up of patients Sciences Group AGM effect on lymphatic function in Chairs: Dr Alp Notghi with NETS patients with breast cancer Dr Jackie James Dr Shaunak Navalkissoor 15.00 TEA, Poster Viewing and Meet S Bains 1, S Allen 2, J Ballinger 2, Y Tan 2, Royal Free Hospital, London Industry L Jenkins 4, A Stanton 3, J Levick 3, 08.30 Changing Landscape for Nuclear A Purushotham 1, A Peters 4, Medicine Trainees: Prepare 11.10 Current Practice and YOUNG INVESTIGATOR PRIZE P Mortimer 3 yourself Controversies in Radionuclide Chairs: Dr Brian Neilly, 1King's College London, Therapy for DTC 2 Dr Liz Prvulovich Dr Margaret Hall Guy's and St Thomas' NHS Institute of Nuclear Medicine, London Dr Ujjal Malick Foundation Trust, Northern Centre for Cancer Care 15.30 49. Optimisation of SUVmax 3St George's, University of London, 4 08.50 The next generation of Medics: Freeman Hospital, Newcastle threshold values in malignant and Brighton and Sussex University Guidance from the BNMS benign lymph nodes (using Hospitals NHS Trust, UK President 11.30 Management strategy in Iodine- iterative and TrueX® Dr Brian Neilly Negative/Thyroglobulin-Positive reconstruction methods) with 16.50 PET Travelling Fellowship 2012 - Patients histological correlation using 18 F- Experience of PET-CT imaging at Glasgow Royal Infirmary FDG PET-CT in patients with head the UniversitatsSpital, Zurich Prof Sobhan Vinjamuri 09.10 Sentinel node imaging: Current Royal Liverpool Hospital and neck squamous cell Dr Alexis Corrigan carcinoma status and future directions Royal United Hospital Bath 11.50 Do’s and Don’ts to maintain a high R Sandhu, A Eccles, L Perry, N Patel, Dr Rosemary Allan St George’s Healthcare NHS Trust quality Therapy Unit – Physicist’s D Towey, E Kauppila, A Al-Nahhas, 17.15 BNMS AGM (Auditorium 2) View Z Win Imperial College NHS Trust, London, 09.30 Liver transplant imaging Richard Fernandez UK Dr Nicola Mulholland Guy’s & St Thomas’ Hospital NHS King’s College Hospital, London Foundation Trust 15.50 50. Are 123 Iodine-mIBG 4 hour SPECT/CT images sufficient for 09.50 PANEL DISCUSSION 12.15 PRIZE PRESENTATION the diagnosis of Phaeochromocytoma/ 10.00 COFFEE and Meet Industry in the 12.30 HIGHLIGHTS LECTURE Paraganglioma? Exhibition Hall Prof John Buscombe R Chakravartty, V Naidoo, Addenbrooke’s Hospital, Cambridge B Corcoran, E Kalogianni, C Hooker, ONCOLOGY II L Devlin, N Mulholland, S Aylwin, Chairs: Prof Adil Al-Nahhas 13.15 COMPLIMENTARY LUNCH and G Vivian Prof Alan Perkins CLOSE OF MEETING Kings College Hospital NHS Trust, London, UK 10.30 Current Practice and Controversies in Radionuclide 16.10 51. BMI: Speeding up BAM Therapy for NETS acquisitions Prof Martyn Caplin C Williams, J Oxtoby Royal Free Hospital, London University Hospital of North Staffordshire, Stoke on Trent, UK

41ST ANNUAL MEETING 1 6 21ST-24TH APRIL 2013 Programme

WEDNESDAY 24 SYNDICATE 1 & 2

ONCOLOGY III 09.45 57. The role of contrast enhanced 10.45 59. Early clinical experience of 12.15 PRIZE PRESENTATION 18 Chairs: Dr Sue Chua, computer tomography in PET-CT dynamic F Fluoroethyl Choline (Auditorium 2) Dr Gordon Ellul in localisation of liver metastases PET-CT(FCH) in differentiating from primary colorectal cancer tumoural/radiation necrosis from 12.30 HIGHLIGHTS LECTURE 08.45 53. Impact of 18 F-FDG-PET-CT on S.J Ong, A.C Gomez, S Whitley, viable brain tumour, compared to (Auditorium 2) the Therapeutic Management of J.R Buscombe combined MRI/DWI. Is combined Bladder Carcinoma Addenbrooke's Hospital, Cambridge, T/B and time activity curve(TAC) 13.15 COMPLIMENTARY LUNCH and UK pattern analysis a reliable CLOSE OF MEETING E Sellon, H Achuth, G Burkill, discriminating tool? S Dizdarevic Royal Sussex County Hospital, 10.00 COFFEE and Meet Industry in the S Chua, HY Loi, J Gear, I Zerizer, Brighton, UK Exhibition Hall D Levine, Y Du, I Chau, I Murray, F Saran 09.00 54. Textural analysis of 18 F-FDG ONCOLOGY IV The Royal Marsden NHS Foundation PET to assess response to Chairs: Dr Teresa Szyszko, Trust, London, UK erlotinib in non-small cell lung Dr Glenn Flux, cancer Dr Sabina Dizdarevic 11.00 60. Assessment of tumour heterogeneity before and after GJR Cook 1, M O'Brien 2, M Siddique 1, CA1P anti-vascular therapy in two 2 2 2 10.30 58. Liver directed treatment with HY Loi , B Sharma , S Chua different metastatic colorectal 1 SIRT in unresectable colorectal KCL, London, models on 125 I-A5B7 (anti-CEA) 2 carcinoma liver metastasis: 4 year Royal Marsden Hospital, London, SPECT imaging UK experience from the Central South Coast of England GJR Cook 1, V Rajkumar 2, V Goh 1, 1 2 2 18 1 1 2 M Siddique , M Robson , G Boxer , 09.15 55. Heterogeneity of F-FDG S Leach , M Kay , B Stedman , 2 1 B Pedley uptake in primary oesophageal F Sundram 1 1 KCL, London, cancers is associated with T and N Department of Nuclear Medicine, 2 stage 2Department of Interventional UCL, London, UK

1 2 2 Radiology, University Hospital GJR Cook , A Davies , C Yip , 11.15 61. Patient-specific tumour 1 1 2 Southampton, UK M Siddique , B Taylor , D Landau , dosimetry for 186 Re-HEDP R Mason 1, V Goh 1 therapy of bone metastases from 1KCL, London, UK prostate cancer 2Guys & St Thomas' NHSFT, UK A M Denis Bacelar 1, A Divoli 2, S Chittenden 2, Y Du 2, D P Dearnaley 2, 09.30 56. CT automatic exposure control 3 2 techniques in PET-CT scanning J M O'Sullivan , G D Flux 1Institute of Cancer Research, Sutton, D Tout 1, G Iball 2, M Waller 2, C Tonge 1 London, 1 Central Manchester University 2Royal Marsden Hospital, Sutton, Hospitals NHS Foundation Trust, London, 2Leeds Teaching Hospitals NHS 3Centre for Cancer Research and Cell Foundation Trust, UK Biology, Queen’s University Belfast, UK

41ST ANNUAL MEETING 1 7 21ST-24TH APRIL 2013 Programme

WEDNESDAY 24 SYNDICATE 3 & 4

08.30 Nuclear Medicine Therapy Group and Technology Research Institute, (Molecular Radiotherapy) Karaj, Iran, Molecular radiotherapy in the UK: 5Jaber Ibne Hayyan Research Toward evidence-based Laboratories, Nuclear Science and harmonisation Technology Research Institute, Tehran, Iran, SPECIAL INTEREST GROUP 6Department of Energy Science, Chairs: Dr Glenn Flux, Sungkyunkwan University, Suwon, Prof Sobhan Vinjamuri Republic of Korea

75 10.00 COFFEE and Meet Industry in the 11.00 64. A New Concept for Se Exhibition Hall SeHCAT studies with a Gamma Camera PHYSICS II WH Thomson 1, J O'Brien 1, G James 1, 2 1 Chairs: Sarah Allen, Dr Alison Bolster M Williams , A Notghi 1City Hospital, Birmingham, 2 10.30 62. Eye Dose measurements in a Velindre Hospital, Cardiff, UK wide range of Nuclear Medicine departments indicate that it is 12.15 PRIZE PRESENTATION unlikely that staff will need to be (Auditorium 2) classified 12.30 HIGHLIGHTS LECTURE J Prince, B Murby (Auditorium 2) The Christie NHS Foundation Trust, Manchester, UK 13.15 COMPLIMENTARY LUNCH and CLOSE OF MEETING 10.45 63. Evaluation of the cyclotron- produced praseodymium oxide radioactivity: Enhancement of the therapeutic properties of 142 Pr 2O3 as a multifunctional agent MK Bakht 1, M Bakhtiari 2, M Hussain 3, M Sadeghi 4, SJ Ahmadi 5, C Tenreiro 6 1Young Researchers and Elites Club, Science and Research Branch, Islamic Azad University, Tehran, Iran, 2Department of Physics, Persian Gulf University, Bushehr, Iran, 3Department of Physics, Government College University Lahore, Pakistan, 4Agricultural, Medical and Industrial Research School, Nuclear Science

41ST ANNUAL MEETING 1 8 21ST-24TH APRIL 2013 Posters

Poster Judging: Monday P1 - P38, CP1 - CP9, Tuesday P39 - P78 P1. Radial quantitative ultrasound in P6 Myocardial Perfusion Studies P11 Outcome of Iodine 131 Therapy for P16 Is 111 In WCC SPECT/CT of value comparison to dual-energy x-ray (MPS) with arms down – could a Hyperthyrodism In Hospital Kuala in patients with clinically absorptiometry in the osteoporosis 360 degree orbit help? Lumpur, Malaysia suspected infection? clinic: An institutional experience J O'Brien, WH Thomson, GD James, Z Awang F Dambha, E Nowosinska, combined with meta-analysis of MM Pandit, A Notghi Universiti Sains Malaysia, Pulau J Buscombe published literature Sandwell & West Birmingham Pinang, Malaysia Addenbrookes Hospital, Cambridge, J Shur, H Hardiman, H Alexander, Hospitals NHS Trust, UK UK AM Peters, S Dizdarevic P12 Value of delayed 131 Iodine- Brighton and Sussex University P7 Incremental value of norcholesterol imaging in primary P17 CASE REPORT: Disseminated Hospitals NHS Trust, UK Lymphoscintigraphy SPECT/MR in aldosteronism (Conn’s syndrome): osteomyelitis or bone metastases lymphangioma chylopericardium Old test revisited of breast cancer: FDG PET-CT P2. Appropriate Referrals for G Rijju 1, G Arun 2, J Vibin 1, G Nissy 1, A Hosur, N Singh, A.M Peters, helps targeting lesion for biopsy Myocardial Perfusion Scans D Dincy 1 E Sellon, S Dizdarevic R Mandegaran 1, A Debard 2, S Thompson, E Winston, 1MIMS, Calicut,Kerala, Brighton and Sussex University M Alvarez 2, B Marchou 2, P Massip 2, N Bhonsele, M Noor, E Elnaas 2MCH, Calicut,Kerala, India Hospital NHS Trust, UK T Wagner 1 Barking, Havering, & Redbridge 1The Royal Free Hospital, London, University Trust, Essex, UK P8 Lipomatous hypertrophy of the P13 The value of pertechnetate thyroid UK interatrial septum; imaging imaging prior to radioactive 2Toulouse University Hospital, P3 Perfusion only technetium scans features on PET-CT Iodine-131I treatment – our Toulouse, France can be used in the management of C. Kelly-Morland, D. Newman, experience young patients with suspected CJ Beadsmoore K Alam, A Notghi P18 Increased operational flexibility pulmonary embolus Norfolk and Norwich University City Hospital, Birmingham, UK through the use of perfusion-only D Newman 1, N Gurjar 1, L Fowkes 1, Hospitals NHS Foundation Trust, UK studies in pregnant patients with A Karuppiah 2, C Beadsmoore 1 P14 CASE REPORT: Lingual thyroid: suspected pulmonary embolus 1Norfolk & Norwich University P9 99m Tc-Nanocolloid SPECT/CT and the role of radioiodine in diagnosis A Gemmell, A Nicol, B Mucci Hospital, a Portable Gamma Camera for and therapy Southern General Hospital, NHS 2 Nottingham City Hospital,UK Image-Guided Sentinel Node M Neilly 2, D Colville 1, O Hilmi 3, Greater Glasgow & Clyde,UK Biopsy in head and neck G McGarry 3, B Neilly 1 P4 A Case Series Review of malignancy: Science & Practice 1Department of Nuclear Medicine, P19 A Pictorial Review of SPECT Interesting Incidental Extra- J Connelly, G Gnanasegaran, Glasgow Royal Infirmary, Ventilation-Perfusion (VQ) Images – Cardiac Findings in Myocardial C Schilling, M McGurk 2University of Dundee Medical Interesting Cases Perfusion Scintigraphy Department of Nuclear Medicine and School, Dundee, CS Low, K Alam, A Notghi, J O'Brien K Alam, A Notghi, J O'Brien, Maxillofacial Surgery Guys & St 3ENT Department, Glasgow Royal Physics and Nuclear Medicine M Pandit Thomas’ Hospital NHS Trust, Infirmary, UK Department, City Hospital, SWBH NHS Trust, Birmingham, UK London, UK Birmingham, UK P15 Error Analysis of SeHCAT P5 Investigation into the Performance P10 “The Glove Phenomenon” – A Rare Retention for Collimated Gamma P20 Use of a Delay Volume Insert for of Resolution Recovery in Extra-osseous Finding on Isotope Cameras Optimisation of SPECT V/Q with 81m Analysing Gated MPI Studies Bone Scintigraphy G James, WH Thomson, J O'Brien Kr A Jennings, J O'Brien, G James, S Eljamel, Z Khan King's College London School of WH Thomson, A Neale, J O'Brien WH Thomson Western General Hospital, Edinburgh, Medicine, City Hospital, Birmingham, UK City Hospital, Birmingham, UK UK City Hospital, Birmingham, UK

41ST ANNUAL MEETING 1 9 21ST-24TH APRIL 2013 Posters

P21 SPECT V/Q with 81mKr. Effect of P25 The significance of uptake in the P29 Pictorial review of PET-CT & P34 Children are not little adults: Our Gas Leakage on Image Quality and thyroglossal tract on 131 I- SPECT/CT in functional imaging of experience of setting up a new Optimisation of the Imaging SPECT/CTscan in thyroid Prostate Cancer: paediatric isotope imaging service Process cancer patients post ablation- and All You Need to Know within an existing District General WH Thomson, J O'Brien, G James, its correlation with TSH and C Sit 1, S Lewitschnig 1, J Connelly 1, Hospital nuclear medicine M Pandit, A Notghi tumour markers S Osmany 2, G Gnanasegaran 1 department City Hospital, Birmingham, UK F Dambha, E Nowosinska, 1Guys & St Thomas' NHS Trust, S Amonkar, L Tandon, R Fernando J Buscombe London, UK Pennine Acute Hospitals NHS trust, P22 Variability of krypton delivery rate Addenbrookes Hospital, Cambridge, 2Radlink PET & Cardiac Imaging Manchester, UK to patients undergoing SPECT V/Q UK Centre, Singapore scans and its impact on clinical P35 Absent bilateral basal-ganglia images P26 Audit of parameters affecting P30 Sentinel Node Biopsy for Head uptake on 18 F- M Burniston, T Wagner, R Leshen, diagnostic quality of FDG-PET and Neck Melanoma: development fluorodeoxyglucose (FDG) PET-CT: scans of a service and initial results A case report with literature review J Page 123 Royal Free NHS Foundation Trust, L Millar, E Kalkman T Aldridge, F Sundram, S John, and comparison to I-DaTSCAN London, UK PET-CT Centre, The Beatson West of G Davies, V Batty, S Sharma findings Scotland Cancer Centre, Glasgow, Dept. of Oral & Maxillofacial Surgery, J Shur, N Kock, G Burkill, P23 Patients of Multicultural Society UK University Hospitals Southampton S Dizdarevic Attending Nuclear Medicine P27 The use of FDG PET-CT in patients NHS Foundation Trust, UK Brighton and Sussex University Department: Breaking the with early operable breast cancer Hospitals NHS Trust, UK Communication Barrier R Duguid 1, A Denison 1, SD Heys 2, P31 “SNL: Torbay ´s Experience” R Sajjan 1, K Al-Nabhani 1, Z Saad 1, L Lovell 1, F McKiddie 1, L Melville 2, A Vaz E Panagiotidis 1, S Salam 2, R Syed 1, S Olson 1, E Ramage 1, S Stafrace 1, EKHFT, Canterbury, UK J Bomanji 1 RT Staff 1 1Institute of Nuclear Medicine, UCLH, 1NHS Grampian, Aberdeen, P32 Molecular imaging of London, 2University of Aberdeen, UK Dermatomyositis-Polymyositis 2Department of Nuclear Medicine, complex: Use of Magnetic Kings College, London, UK P28 SPECT/CT Sentinel Lymph Node Resonance Imaging, Bone Scan Biopsy: Adding more to hotspots and 18 F-FDG PET-CT as an P24 A Study of Delayed Cardiotoxicity C Sit, J Connelly, M Hosahalli, investigational tool in Trastuzumab treatment using G Gnanasegaran S Bhatia, A Haroon, F Karim, multi gated acquisition scans Guys & St Thomas' Hospital NHS K Centa, K L Tan, C Padmanathan, (MuGA) Trust, London, UK H Jan E Gill, J Buscombe Barts Health NHS Trust, London, UK 1University of Cambridge, 2Addenbrooke's Hospital, Cambridge, P33 Counteracting brown fat: an audit UK on the introduction of beta blockade in paediatric FDG PET- CT D Neriman, R Allie, L Menezes Institute of Nuclear Medicine, University College London Hospital, UK

41ST ANNUAL MEETING 2 0 21ST-24TH APRIL 2013 Posters

P36 Early detection of recurrence of P39 Medical Imaging Utilising P43 Whole Body PET-CT vs P48 FLT PET breast cancer exhibits 3D colorectal carcinoma on 18 F-FDG Zirconium Complexes Conventional CT in the Staging of fractal characteristics pre and PET-CT and its correlation with T Ferris, P Charoenphun, M Went, Lung Cancer during therapy other clinicopathological P Blower L A Fowkes, C J Beadsmoore, B Sanghera 1, L Sonoda 1, D Woolf 2, parameters 1The University of Kent at Canterbury, M Crawford A Makris 2, W Wong 1 H Ahmed 1, H Bashir 1, 2King's College London, UK Norfolk & Norwich University 1Paul Strickland Scanner Centre, M Khalid Nawaz 1, Z Faruqui 2, Hospital, UK Mount Vernon Hospital, A Saeed Kazmi 3, A Ali Syed 4, P40 CASE REPORT: Increased FDG 2Mount Vernon Hospital, UK S Khattak 4, M Azam 1 uptake in PET imaging of intra- P44 Comparison of FDG PET-CT 1Shaukat Khanum Memorial Cancer ocular prosthesis in a patient with characteristics of adenocarcinoma P49 PET-CT in Interstitial Lung Disease Hospital & Research Center, Nuclear previous choroidal melanoma and squamous cell carcinoma of L Millner 1, A Groves 1, J Porter 1, Medicine, 1 1 1 the oesophagus 2 3 1 2 S Haldar , S Dizdaveric , G Burkill , T Maher , T Win , B Hutton , Shaukat Khanum Memorial Cancer J Hungerford 2, V Raman 1 T Westwood, T Ransome, J Hill R Shortman 1, R Endozo 1, Hospital & Research Center, 1Brighton & Sussex University Royal Preston Hospital, UK B Ganeshan 1, P Lukey 4 Radiology, 1 3 Hospitals, University College Hospital, London, Shaukat Khanum Memorial Cancer 2Moorfields Eye Hospital, London, UK P45 Correlation between Textural 2Royal Brompton Hospital, Hospital & Research Center, Medical Features of 18 F-FDG PET in 3Lister Hospital, Stevenage, Oncology, P41 Imaging Hypoxia- The Synthesis of oesophageal cancer 4GlaxoSmithKline, Stevenage, UK 4Shaukat Khanum Memorial Cancer Asymmetric Copper (II) M Siddique, V Goh, P Marsden, Hospital & Research Center, Surgical Bis(thiosemicarbazones) P50 Review - Can treatment response Oncology, B Taylor, M Frost, G Blake, G Cook 1 2 be predicted using FLT PET-CT ? 5Shaukat Khanum Memorial Cancer O Brown , J Bagunya Torres , King's College London, UK Hospital & Research Center, M Went 1, P Blower 2 B Sanghera 1, L Sonoda 1, D Woolf 2, Pathology, Lahore, Pakistan 1University of Kent, Canterbury, P46 Investigation into effects of Time A Makris 2, W Wong 1 2Kings College, London, UK of Flight, Resolution Recovery and 1Paul Strickland Scanner Centre, P37 How Sharp is “SharpIR”? Reconstruction Iterations on Mount Vernon Hospital, P42 Value of 18 F FDG-PET-CT brain reconstructed PET images 2Mount Vernon Hospital, UK N Vennart, I Cullum, N Bird imaging in the syndromic acquired using a GE Discovery 690 Cambridge University Foundation characterization of primary PET-CT System P51 FLT PET-CT breast cancer Hospitals Trust, UK progressive speech disorders C McKeown, MF Dempsey, G Gillen, distinguished with 3D lacunarity 1 2 2 analysis pre and post therapy P38 Patient hyperhydration and J Shur , KK Moodley , D Chan , J Prosser, C Brown delayed urinary bladder studies G Keramida 1, G Burkill 1, S Dizdarevic 1 NHS Greater Glasgow and Clyde, UK B Sanghera 1, L Sonoda 1, D Woolf 2, improve 18 F-Flurodeoxyglucose 1Brighton and Sussex University A Makris 2, W Wong 1 (18 F-FDG) PET-CT detection of Hospitals NHS Trust, P47 Cardiac 82 Rb PET: Development 1Paul Strickland Scanner Centre, bladder wall neoplasms 2Clinical Imaging Sciences Centre, of Practice Mount Vernon Hospital, Brighton and Sussex Medical School, 2Mount Vernon Hospital, UK 1 1 1 D Tout, I Armstrong, C Tonge, E. Perrone , F. Barbano , E. Calò , University of Sussex, UK A. Cisternino 2, G. Valle 3 P Arumugam 1PET Unit of the Scientific Institute Central Manchester University Casa Sollievo della Sofferenza, Hospitals NHS Foundation Trust, UK 2Urology Unit of the Scientific Institute Casa Sollievo della Sofferenza, 3Nuclear Medicine Unit of the Scientific Institute Casa Sollievo della Sofferenza, Italy

41ST ANNUAL MEETING 2 1 21ST-24TH APRIL 2013 Posters

P52 Impact of matching SUV recovery P56 Quantitative Image Reconstruction P61 Comparison of Nuclear Medicine P66 Metrology for 90 Y Microspheres or background noise on signal to using Anatomical Information staff finger doses in a Department A Fenwick, M Baker, K Ferreira, noise with advanced PET during Reconstruction with PET-CT facilities to those L Johansson reconstructions 1 2 observed from the Pan European S Cronin , M Partridge , 1 National Physical Laboratory, IS Armstrong 1, MD Kelly 2, A Denis Bacelar 1, G Flux 1 ORAMED study Middlesex, UK HA Williams 1, JC Matthews 3 1The Institute of Cancer Research & J Cullis, N Williams, C Koller 1Central Manchester University Royal Marsden Hospital, London, University Hospital Coventry, UK P67 qDose, a treatment planning tool Hospitals, 2Gray Institute for Radiation Oncology for individualised, dosimetry based 2Siemens Healthcare, Oxford, & Biology, Oxford, UK P62 Radiation Dose Considerations for radionuclide therapy 3 81m University of Manchester, UK Patients and Staff for Kr V/Q KJ Frisch 1, AM DenisBacelar 1, P57 Pixon® Planar Processing SPECT J Gear 2, G Flux 2 P53 Can an ECG simulator be used to Improves Lesion Detection for 1 123 WH Thomson ICR, London, generate reduced count SPECT I-mIBG Studies City Hospital, Birmingham, UK 2Royal Marsden Hospital, London, data? N Bebbington, L Jenkins, M Wilson, UK CM Brown 1, G Gillen 2, J Prosser 2, E Lanchbury, S Holt P63 Radiosynovectomy in patients with MF Dempsey 2 The Queen Elizabeth Hospital Haemophilia: Science & Practice P68 Lung shunting estimation in 1University of Glasgow, Birmingham, UK selective internal radiation therapy 2 J Connelly, A Desai, S Austin, Gartnavel General Hospital, D Back, S Vijayanathan, (SIRT): additional value of scatter Glasgow, UK P58 Radionuclide Calibrator Linearity G Gnanasegaran correction and SPECT/CT Tests – Taking Greater Care to Departments of Nuclear Medicine, E Varzakis, L Bolt, F Sundram, P54 Is SPECT contrast recovery of the Save Time? Radiology, Haemophilia & M Guy PET NEMA IEC Body phantom S Dainty, C Williams, R Morton Orthopaedics Guy’s & St Thomas University Hospital Southampton dependent on sphere positioning? University Hospital of North Hospital NHS Foundation Trust, NHS Trust, UK CM Brown 1, G Gillen 2, J Prosser 2, Staffordshire NHS Trust, Stoke-on- London, UK MF Dempsey 2 Trent, UK P69 Practical patient-specific bone 1University of Glasgow, P64 Liver directed treatment with marrow and organ dosimetry for 2Gartnavel General Hospital, P59 An Audit of Image Uniformity in selective internal radiation therapy Yttrium-90 radio-labelled anti- Glasgow, UK SPECT Imaging (SIRT): 4 year experience CD66 MAb molecular radiotherapy

99m M Avison M Kay, S Leach, B Stedman, MJ Guy, J Langford, G Lewis, P55 Reduced Dose/Time Tc MIBI Bradford Teaching Hospitals NHS F Sundram KH Orchard Myocardial Perfusion SPECT Foundation Trust, UK University Hospital Southampton, UK University Hospital Southampton, UK (MPS) with Resolution Recovery (GE: Evolution for Cardiac) versus P60 CT Numbers in SPECT/CT: an P65 Single dose chemotherapy for Full Time MPS with FBP and RR: unstable calibration or just chasing seminoma: Is a four sample GFR Is reduced count data errors? appropriate? diagnostically acceptable? A Smout 1, J Hall 2, A Fullbrook 2, J Cullis 1, R Penny 1, A Dumbill 2, S Michopoulou, J.C Dickson, J Ward 2, L Wright 2 N Williams 1 E Panagiotidis, R Sajjan, 1Royal Surrey County Hospital, 1University Hospital Coventry, W.A Waddington Guildford, 2University Hospital Birmingham, UK Institute of Nuclear Medicine, 2Frimley Park Hospital, Surrey, UK University College London Hospital, UK

41ST ANNUAL MEETING 2 2 21ST-24TH APRIL 2013 Posters

P70 Molecular radiotherapy: how much P74 Accuracy of single sample CLINICAL PRACTITIONERS POSTERS CP6 Extending the technologist role in dose is the patient really getting? techniques for assessment of initiating plain radiographs and V Smyth 1, C Bobin 2, L Johansson 1, Glomerular Filtration Rate (GFR) CP1 Optimisation of Scatter Correction SPECT/CT at bone scintigraphy M d'Arienzo 3, M Cox 1, J _olc 4 and their dependence on sampling and the Addition of Time of Flight K Jandu, R Harris, A.R O'Connor 1National Physical Laboratory, time, renal function and Improves Uniformity in Large PET Nottingham University Hospitals NHS Teddington, UK, extracellular fluid volume (ECFV) Phantom Studies Trust, UK 2Laboratoire National Henri Becquerel F Wickham, H McMeekin, G Pawson, I.S Armstrong, P Hogg of the Commission for Atomic M Burniston 1Central Manchester Foundation CP7 Interfering PETs and the Energy, Saclay, France, Royal Free London NHS Trust, UK Trust, importance of SeHCAT 3The National Institute of Ionising 2University of Salford, UK backgrounds Radiation Metrology, Rome, Italy, P75 VQ SPECT : A first line 4 L.A Holmes, D.A Pearce, L Sanders Cesky Metrologicky Institut Brno, investigation for all patients CP2 A movement correction strategy Queen Alexandra Hospital, Brno, Czech Republic M Jafari 1, E Jefferson 2, A Mackie 2, for static images using dynamic Portsmouth, UK I Minty 3 acquisition and registration P71 Radiopharmaceutical and Nuclear 1University Hospital of North Durham, software CP8 51 Cr (EDTA) Glomerular Filtration Medicine Imaging Characteristics 2 99m Regional Medical Physics L Lovell, J Wright, J Robinson, Rate (GFR) studies: Is it necessary of Tc Water Soluble Chitosan Department, County Durham and R Staff to consider residual activity? Derivatives Darlington NHS Foundation Trust, Nuclear Medicine, Aberdeen UK K Lee, R Penny, J Cullis, N Williams H Farag 1, R Hassan 2, Dl El-Hawary 3, 3Department of Clinical Radiology, 4 University Hospital Coventry and M Motaleb County Durham and Darlington NHS CP3 Accuracy of Glomerular Filtration Warwickshire, UK 1Department of Nuclear Engineering, Foundation Trust, UK Rate calculation from variable Faculty of Engineering, Jeddah, blood sampling frequency CP9 The feasibility and appeal of a Saudi Arabia, P76 The importance of patient 2 TM A Nunes, M Luqman, E O’Mahoney, solely e-based module to develop Department of Nuclear Medicine, positioning with IQSPECT M Newell, H Jan new skills & knowledge for non- National Cancer Institute, Cairo, A. Paramithas, A.G Irwin Barts Health NHS Trust, London, UK medical healthcare practitioners Egypt, St. George's Hospital, London, UK 3Department of Chemistry, Faculty of P Delf CP4 In-house preparation and clinical University of Portsmouth, Hampshire, Science, Cairo University, Egypt, P77 CASE REPORT: A diagnostic validation of 111 In--DTPA for oral 4 UK Department of Labeled Compounds, challenge of a rare case of use in whole gut transit studies Hot Labs Center, Atomic Energy perirenal extramedullary Authority, Cairo, Egypt K Solanki, A Wong, W Oware, haematopoiesis – the role of C Solanki nanocolloid bone marrow imaging P72 Comparison of two methods for Addenbrookes Hospital, Cambridge, labelling white cells with 111 In-oxine K Alam, M Pandit, B Wee, J.O Brien UK City Hospital, Birmingham, UK E Papadopoulos, GA Wright, CP5 A review of the impact of G Avery P78 99m Tc-MDP Bone SPECT/CT in SPECT/CT introduction to a Hull and East Yorkshire Hospitals Trauma & Sports Injures nuclear medicine clinic and the NHS Trust, UK N Shur, C Sit, J Connelly, A Desai, learning outcomes P73 MAG3 renography revisited S Vijayanathan, G Gnanasegaran R Harris, K Jandu, C Kalirai Guys & St Thomas’ Hospital NHS Nottingham University Hospitals NHS P.S Cosgriff, M Aslam Trust, London, UK Trust, UK United Lincolnshire Hospitals, Boston, UK

41ST ANNUAL MEETING 2 3 21ST-24TH APRIL 2013 Finding your way to the Brighton Centre

How to get there

The Brighton Centre is located on the seafront, on Kings Road, between The Grand Hotel and the Odeon cinema.

Brighton Centre King’s Road Brighton BN1 2GR

By Air

The nearest airport is London Gatwick, 30 minutes away by train. Heathrow airport is 90 minutes by car, coach or taxi.

Parking

There are three NCP car parks located behind the Brighton Centre (one of which serves Churchill Square shopping centre and is the easiest to get in and out of). There are also disabled parking bays at the top of nearby Cannon place where you can park for free with a blue badge, and which are just a five- minute walk from the centre.

Please visit the PET website to see preferential delegate and exhibitor rates for the Regency Square car park.

Public Transportation

The nearest British Rail station is Brighton. It is a ten minute walk from the train station but there is a bus stop on route X11 directly outside the centre.

41ST ANNUAL MEETING 2 4 21ST-24TH APRIL 2013 Finding your way around Brighton

m N

B d P 21 o 2 e e

0 R n r t c id Rd t A2 w oldsm 010 o a d G S S g r

N v r r

iz h E

e s e n e t R ll t i e s i A n v d T a n S ve e l v

d d d A r

B e o c g h e n t G n Y n R a t n a S t l v c d o a r t a o

c t o r S S d m n m p i R H d l n r n e a e l e l o d St Ann’s Well i R k a t n T m d s n D h o g o H a R P e H

s s l n t o P C in C S l l e s t

l w

u BRIGHTON l l o Gardens f l h i e S i o t d n l e s e n o h r i n D W L a H r v i u e C t A RAIL t W t e y m S W V West A h S Hill r k d k Rd n o m r 2 t R e v e e e r o 3 o T v r a Y n a S o R S w t T h t E if d t rafa ill l d lgar w R S H e C St e B e 21 t t z 3 N r c d 0 19 u C r S F a m t 2 S li 1 y e r f a o t t S A r o f 0 n A e d c l S h s n i r l L a e 2 o b r e t a R g u t i e n r T H A e i v S t s l o J d r n S b l i v o d k l i l i n ow e l G r t S l r k n n k H H S T r y A G a e o O t l P V i l R c d e a t d e l d Y k ic i S l o n t n l l to P u v a S e S H l r o t T t o m ia n o c w n P f w B r o d R S e i k d r n s D o c o d b w k G t G S R o e c e R d i y d r y u o c d r r g i N D s e k Q R d R e d n t i l n m w g s e r k s d n s P S A s a d n a l a i c l e u n r b R R L n i d n i a r C r i o F o o e e c u d lif h h n F R t d 0 b t m L w o h H r n F R t T t K s o o i s e c 1 n l k r i S J d l B m r e r S 0 S n k C w N t a l li N o M ft e 2 r c u o t o e o on t K h R r l d u C n Y f G W tp d S A e r p e n o M s B te lie s l or t rn R o r Ch ley d m t Te u G St S B2 N rr rc 066 e S ac h T 2 e B St S y g l u e 2 2 t ss l n P e 1 i e x n 1 e S q r e t a 2 2 t h t S l p r d 1 C g t S t S B S h a P k u u r r r S S d W c c d h o i e a r st t o S r Ki t d R er d t n n s s o P gs w o R w t f S d n o S R t d o s d o e b d n a l S d d S r o e n l t n o S i a e t n o C t W n t e r u o i a C l r s r B M a l t W a le o S r r w e l S r lto B t e i t t n e P H t s p S N G m S ill o a e t S a il rt i l w t n o h l n od S l W W i P o S S tr h t e K Churchill e o t i y t ng n W t sw M r J n a o y u o S A2 t Square 5 b 9 s s m e s l e e n r w n P t B r o t P e e e 2 Ed g n wa s e 0 r l e d E M S l o r 6 t i u t R t 6 T n us S Q se n S ll t E R t a d e dw t e t a S rd S K g S in C s n r S t g i l ’ e t s e l e o R e o S t h d e a e d p W P S g r i d A p in n G a i 25 i ce i 9 d H h h A l lb e M e r t C Kings Road, Brighton S t St O St S Jam es’s S East Sussex BN1 2G d t E l

A a 2 O B Tel: 01273 290131 59 s 21 Ki t 18 ng’s www.brightoncentre.co.uk Rd S t ion Rd and Junct Gr Ma M rine English Channel aderia Para Drive de

Brighton Pier

41ST ANNUAL MEETING 2 5 21ST-24TH APRIL 2013 Exhibiting companies and exhibition floor plan

Our thanks to the following companies for supporting our meeting.

Stand no. Alliance Medical 8 Amercare 4 Aquila 6 Ashby GB 19 Bartec 28 Bayer 3b BNMS 29 Bright Technologies 21 College of Radiographers 5 Covidien 20 Diagnostic Imaging 22 Endocyte, Inc 13 Erigal 27 GE Healthcare 24 Hermes 10 IBA Molecular 11 Imaging Equipment 26 Immunomedics 16 InHealth 25 Lablogic/Southern Scientific 7 Lilly UK 14 Link Medical 18 Mirada Medical 12 Oncology Imaging Systems 15 ONET Technologies 17 Philips Healthcare 1 Raytest 3 Siemens 23 Sirtex 3a

41ST ANNUAL MEETING 2 6 21ST-24TH APRIL 2013 Exhibiting companies

Stand No. 8 Stand No. 19 Stand No. 21 Stand No. 22 Alliance Medical is the leading provider of Ashby Gorman Baker is the largest independent Bright Technologies Ltd , often known as Bri Tec, Diagnostic Imaging Limited is the exclusive independent imaging services including PET-CT, nuclear medicine service organisation in Europe. We has a renowned reputation for its expertise in supplier of SmartVent, the best selling radioaerosol MRI, CT and X-ray and Ultrasound. Commanding a specialise in the maintenance and repair of many Radiation Protection, Radioactive Material Handling, delivery system in the UK. We also supply a wide large mobile fleet and many fixed site partnerships, different Gamma Camera systems from a variety of Shielding, Radio-Pharmaceutical Q.C., and MRI range of radiopharmaceuticals and radioisotopes all supported by an extensive team of highly skilled manufacturers. We have offices in several European Accessories. A key feature of Bri Tec is our Sheffield from a number of manufacturers, plus the exciting Radiographers. Alliance Medical provide PET Countries with our Headquarters and main training based in-house design and manufacturing facility. new range of gamma cameras from DDD. Please imaging services that include; a mobile PET service, centre being based here in the UK. We are very We have wide ranging experience of working with visit our stand to discuss with us how we can help fully managed PET-CT static facilities and proud of the reputation we have earned for providing many NHS Trusts, Further Education Institutes and you. radiopharmaceutical supply. excellent, professional and totally customer focused commercial companies. Our in-house design team service to our customers, which is cost-effective and and production facility allows us to take your ideas Stand No.13 Alliance Medical have operated the DoH NHS PET- of the highest possible quality. We are pleased to and designs, develop them and, put them into Endocyte, Inc. is a biopharmaceutical company CT North Contract for the last five years: have this opportunity to support the PET and look production. This versatility allows Bri Tec to developing targeted therapies for the treatment of *Providing patients with rapid access to local forward to welcoming you to our stand. undertake both low and high volume production cancer. Endocyte uses its proprietary technology to services *Ensuring the best possible care Tel 01923 400343 runs. In addition we are able to bespoke create novel SMDCs and companion imaging *Clinical reporting by NHS specialities *Seamless Tel (Belgium): + 32 (0) 9 296 23 05 manufacture room installations so that the room diagnostics for personalized targeted therapies. The integration with existing services www.ashbygb.com space is optimally utilised in terms of both space company's SMDCs actively target receptors (e.g. and user friendliness. What do we mean by this? folate receptors and PSMA) that are over-expressed If you have any questions about a PET imaging Stand No. 6 The installation fits both the user’s requirements and in diseased cells, relative to healthy cells. This service and the different options for gaining access Aquila team has a total of over 200 years combined the room – not the other way round! Contact us: targeted approach is designed to enable the to PET, please visit the Alliance Medical stand to talk experience in the nuclear medicine industry which Bri-Tec House treatment of patients with highly active drugs at to one of our representatives or to pick up a includes the specialist areas of containment, 1 Holbrook Commerce Park, Holbrook Close, greater doses, delivered more frequently, and over brochure. Contact:Tel: 01926 482222 or email: shielded facilities, remote handling and packaging Sheffield S20 3FJ, Tel: +44 (0)114 251 1215 Fax: longer periods of time than would be possible with [email protected]. Alternatively, you can visit our for radioisotopes. Our engineers have been involved +44 (0)114 251 3831 the untargeted drug alone. The companion imaging website at www.alliancemedical.co.uk. in projects from the design concept stage right E-Mail: [email protected] Web: diagnostics are designed to identify patients whose through to manufacturing, testing, installation and www.britec.net disease over-expresses these targets and who are Stand No. 4 commissioning at our clients’ sites. Clients engage therefore more likely to benefit from treatment. Amercare have been the leading UK manufacturers with Aquila at different stages in the delivery Stand No. 5 of Isolators for all Radiopharmacy and Pharmacy process, but we like to get involved as early as College of Radiographers is committed to Stand No. 27 applications for over 20 years. We design and possible so that we can share best industry practice developing and promoting the science and practice Erigal is the leading provider in the United Kingdom manufacture isolators for Nuclear Medicine from the start, saving time, money and delivering of medical imaging and radiation therapy. We are and Ireland of radiopharmaceuticals for Positron applications such as Technetium Dispensing and exactly to our clients’ requirements. Contact: Dave the unified voice of radiographers and associated Emission Tomography. Our business is built around Blood Cell labelling plus specialist isolators for Myers [email protected] Tel: 01962 717015 practitioners in clinical practice, education and the principles of quality and reliability. Recognising Iodine, PET, Gallium etc. We also provide servicing, www.aquilaeurope.eu research and develop and promote policy on current the importance of service continuity, we aim to validation and spares support for all our isolators. and emerging educational, professional and deliver the most reliable supply of high quality Amercare also manufacture the Amercare Stand No. 28 workforce issues related to nuclear medicine. We radiopharmaceuticals. Our RPU facilities are all Automated Dose Dispenser for safe dispensing of Bartec specialises in the supply, delivery, installation provide our members with a range of services designed to optimise product quality, production highly active isotopes into syringes or bottles. We and support of Nuclear Medicine equipment and including workplace and employment representation, capacity and reliability. also supply isolators for non-radioactive applications accessories including radiation monitoring, a range of publications including a quarterly peer such as Chemotherapy, CIVAS, TPN and Sterility protection and decontamination products. Bartec’s review journal and online continuing education Our commitment to quality and reliability is testing. Contact: Graham Wilson, Tel: 01844 partners in the UK are: Mediso imaging systems, resources. We welcome visitors to our stand where demonstrated by our investment in the 261244 Biodex Medical Systems for Nuclear Medicine our representatives will be on hand to discuss a establishment of an un-rivalled network of 4 GMP- Email: [email protected] Accessories, Data Spectrum Corporation for wide range of topics, including regulation, workforce licensed production facilities in the UK and Ireland. www.amercare.co.uk Specialist Imaging Phantoms and Eckert & Ziegler shortages and development, education and training, These are in Dublin, Keele, Preston and Sutton for Calibration sources. In addition Bartec provides continuing professional development, etc. So, (Surrey). Each of these units has a minimum of 2 refurbished Gamma Camera systems primarily to the please visit us – members and non-members are all clean rooms for routine production of Veterinary market.www.bartectechnologies.com and very welcome. radiopharmaceuticals, providing a unique back up www.mediso.hu capability. In addition to FDG, Erigal currently manufactures both F-Choline and Sodium Fluoride. Other tracers are under development.

41ST ANNUAL MEETING 2 7 21ST-24TH APRIL 2013 Exhibiting companies

Keele University Science Park, imaging needs. Whether it be longitudinal tumour consolidating role in the industry. IBA is more injectors, Radionuclide therapy, extensive shielding Keele, Staffordshire, ST5 5BX United Kingdom tracking in Oncology, database design to committed than ever to the future of nuclear and radiation protection; from some of the worlds’ Tel: +44 1782 667 680 Fax: +44 1782 667 681 differentiate Alzheimer ´s Disease & Fronto - medicine, as a whole, and IBA Molecular Imaging, in most respected manufacturers including ROTOP, www.erigal.co.uk Temporal Dementia, advances in cardiac PET particular. We will endeavour to continue to provide Tema, Eckert & Ziegler, Von Gahlen and Fluke, imaging or bridging Radiology, Nuclear Medicine & patients with early detection, better characterization enables us to accurately match customers’ Stand No. 24 PET, HERMES is leading the way. HERMES is a and real-time monitoring of cancer and other major requirements and to build packages that meet both GE Healthcare provides transformational medical vendor-neutral, uniform processing platform for diseases. with the continuing growth and technical specification and budgetary demands. technologies and services that are shaping a new Nuclear Medicine, PET-CT/MR and Multi-Modality development of our radiopharmaceutical business. Our team of specialist Nuclear Medicine sales age of patient care. Our broad expertise in medical imaging. HERMES maintains image data integrity We believe we can build upon a solid business consultants, supported by a dedicated and imaging and information technologies, medical across all vendor platforms, providing you with the foundation by leveraging our unique strengths and experienced technical team, provide a personal, diagnostics, patient monitoring systems, drug freedom of choice for new camera purchases. capabilities to drive future value by enhancing its high-quality service to customers across the UK and discovery, biopharmaceutical manufacturing Hermes Medical Solutions Ltd manufacturing assets, expanding its geographic Ireland. We offer expert product demonstrations technologies, performance improvement and Grove House, 2 Orange Street, London, WC2H 7DF coverage, and investing in new product and well-supported trial periods that enable performance solutions services help our customers Phone: 020 3178 5890, Fax: 020 3178 6101 development". customers to make detailed technical decisions. Our to deliver better care to more people around the E-mail: [email protected] Contact: Mike Ward, 07973 444394 sales consultants continue to take a leading role in world at a lower cost. In addition, we partner with Website: www.hermesmedical.com [email protected] helping to disseminate knowledge and research healthcare leaders, striving to leverage the global Contact: Jan Bertling CEO Tel: 01483 301638 related to some of the most cutting-edge nuclear policy change necessary to implement a successful www.ibamolecular. imaging techniques, and in doing so have supported shift to sustainable healthcare systems. Stand No. 11 departments and patients alike. IBA Group develops and markets leading edge Stand No. 16 Our “healthymagination” vision for the future invites technologies, pharmaceuticals and tailor-made Immunomedics GmbH is a subsidiary of IEL is dedicated to connecting nuclear medicine in the world to join us on our journey as we solutions for healthcare with a focus on cancer Immunomedics, Inc., a New Jersey based the UK and Ireland to world’s leading healthcare continuously develop innovations focused on diagnosis and therapy. biopharmaceutical company primarily focused on products. reducing costs, increasing access and improving the development of monoclonal, antibody-based Contact: Tel: +44 (0)1761 417402 quality around the world. Headquartered in the In 2012 IBA and SK Capital Partners, a U.S. based products for the targeted treatment of cancer, Fax: +44(0)1761 413600 United Kingdom, GE Healthcare is a unit of General private investment firm, announced that they have autoimmune and other serious diseases. The Electric Company (NYSE: GE). Worldwide, GE entered into an agreement to create IBA Molecular company has developed a number of advanced Stand No. 25 Healthcare employees are committed to serving Imaging. Molecular imaging is one of the most proprietary technologies to create humanized InHealth Limited is the UK’s leading provider of healthcare professionals and their patients in more advanced and exciting fields in medical diagnostics. antibodies that can be used either alone in unlabeled diagnostic and imaging services. It has delivered than 100 countries. For more information about GE The SK Capital involvement will reinforce IBA's or “naked” form, or conjugated with radioactive over 800 contracts for NHS and private providers Healthcare, visit our website at molecular imaging capabilities by enhancing its isotopes or chemotherapeutics, in each case to including PET-CT, MRI, X-Ray, DXA, ultrasound, www.gehealthcare.com. manufacturing capabilities, generating new products create highly targeted agents. The European mammography, echocardiography, interventional and expanding its geographic coverage. The new headquarters is Marketing Authorisation Holder of cardiology, ENT and audiology. InHealth delivers Stand No. 10 tracers will help to identify kidney cancer and LeukoScan®, an antibody fragment approved for the South of England PETCT Service on behalf of Hermes Medical Solutions was established in Alzheimer's disease earlier than ever previously the scintigraphic diagnosis of osteomyelitis including the NHS. InHealth was the first UK provider of PET 1976 in Stockholm, Sweden, and is a leading imagined. These unprecedented medical diabetic feet. LeukoScan is distributed by scanning services outside the NHS. It now operates innovator in medical imaging hardware/software breakthroughs have the potential to save countless Immunomedics GmbH into more than 20 countries a number of static and mobile PET-CT facilities products for health care facilities worldwide. lives and give hope to patients and their families. including UK. including the UK's first independent PET-CT Centre HERMES delivers a wide range of medical imaging Our objective is to ensure that IBA Molecular Contact: Immunomedics GmbH, with a Cyclotron. For more information contact solutions to optimize hospital workflow for your local Imaging can strengthen its position in the nuclear Otto-Röhm-Str. 69, 64293 Darmstadt [email protected] or 0845 045 3666. requirements. medicine market and reach its full potential of Contact: Dr. L. Greiner-Bechert, Vice President For information on the South of England PET-CT providing patients with early detection, better European Operations Service please contact 0845 600 2953 or email HERMES software - designed for your clinical characterization and real-time monitoring of cancer Phone: +49 6151 6671566, Fax: +49 6151 inl.petctsouth.nhs.net www.inhealthgroup.com imaging needs: Fighting illness & disease requires and other major diseases. 6671577Email: [email protected] state-of-the-art imaging modalities & software in Stand No. 7 order to diagnose accurately, stage disease The premium position of IBA in the field of molecular Stand No. 26 Lablogic iis the leading manufacturer and supplier appropriately & select the best treatment available. imaging will not only lead the sector towards Imaging Equipment Ltd IEL is the largest of innovative Quality Control equipment and HERMES partners with the best institutions globally improvements in healthcare through the broader independent distributor of specialist Nuclear Laboratory information Management Systems (LIMS) to continually deliver customized diagnostic software application of molecular imaging but also, if the Medicine products in the UK and Ireland. Our wide for PET and SPECT applications. We can source, packages to meet your ever-changing medical opportunity arises, will enable it to potentially play a portfolio that includes Radiopharmaceuticals, PET supply, install and validate the complete range of

41ST ANNUAL MEETING 2 8 21ST-24TH APRIL 2013 Exhibiting companies

equipment needed in order to operate your QC Stand No. 18 Stand No. 17 Stand No. 3 facility. LabLogic’s products and services allow you Link Medical Limited are specialists in the provision ONET Technologies UK Ltd provides a complete Raytest is a world leader in the design and to establish and operate your research or routine of imaging software for Nuclear Medicine and design and build service for the provision of manufacture of specialised systems for the PET facility efficiently and with confidence. Our state Radiology departments. Many UK and customers radiopharmaceutical process equipment ranging measurement and detection of radiation, supplying of the art equipment and cutting edge software is use Link Medical to provide solutions for from research hot cells and cyclotron support rugged, reliable, precision instruments to backed by full operations training and validation Networking, PACS Connectivity, Image Fusion, equipment to GMP production facilities for radiochemists in PET, nuclear medicine, and documentation to ensure GMP compliance. In Image Processing and many other applications. producing technetium generator, iodine seeds, and pharmaceutical research. The Raytest product addition LabLogic is the only supplier of PETra, a More recently, Link Medical have obtained a radiopharmaceuticals for PET and SPECT. range includes: dedicated PET Laboratory Information Management Wholesale Dealers Licence from the MHRA allowing Visit: www.onet-technologies-UK.com System (LIMS). PETra manages the complete the distribution of Radiopharmaceuticals. We now Tel: 01489 897 315 Synthesis systems for automated radio labelling and process in PET facilities, including batch records, supply an increasing number of UK radiopharmacies chromatography. inventory, SOPs, equipment maintenance logs, with products from Medi-Radiopharma and IDB, Stand No. 1 trending, label design, etc. For more information including the recently licensed Med-Exametazime Philips Healthcare - Transforming care, together. Laboratory instrumentation, including HPLC, GC, please visit us on our stand HMPAO for brain and infection imaging. We will be Philips is a diversified health and well-being TLC and a multichannel analyser. Contact: LabLogic Systems Limited, delighted to discus your requirements at PET 2013 company and a world leader in healthcare, lifestyle Paradigm House, 3 Melbourne Avenue, Broomhill, in Brighton on our stand. and lighting. Our vision is to make the world A LIMS system, providing a single consolidated Sheffield, S10 2QJ, Contact: Peter Dobson, Link Medical Ltd, healthier and more sustainable through meaningful report for all QC tests. Tel: 00 44 114 266 7267 Tel: +44 (0)118 932 6850 innovation. We develop innovative healthcare Robert Woodcock Mobile: +44 (0)7527 844022 solutions across the continuum of care, in A range of preclinical scanners including PET-CT, E-mail: [email protected] [email protected] partnership with clinicians and our customers to PET/MR and CT improve patient outcomes, provide better value, and Stand No. 14 Stand No. 12 expand access to care. As part of this mission we Whenever you need accurate, precise, reliable Lilly, a leading innovation-driven corporation, is Mirada Medical is an internationally recognized are committed to fueling a revolution in imaging radiation measurement, Raytest has a solution. developing a growing portfolio of pharmaceutical brand in advanced medical imaging. The company solutions, designed to deliver greater collaboration Please visit the raytest booth to discuss your products by applying the latest research from its produces technologically advanced, vendor neutral, and integration, increased patient focus, and specific requirements. own worldwide laboratories and from collaborations software applications, which are used across nuclear improved economic value. We provide advanced with eminent scientific organizations. Headquartered medicine, diagnostic radiology, radiation oncology imaging technologies you can count on to make Stand No. 23 in Indianapolis, Ind., Lilly provides answers -- and elsewhere. XD3, Mirada Medical's Image review confident and informed clinical decisions, while Siemens offers a wide and extensive range of through medicines and information -- for some of software, offers validated, industry-leading providing more efficient, more personalised care for Molecular Imaging solutions, including the Symbia S, the world's most urgent medical needs. Lilly has a deformable registration to allow clinicians to fuse patients. a flexible, large field of view dual head system, with long heritage in the UK, opening its first facility and view multi-modalities including PET- the option for fully automated daily quality control outside North America in London in 1934. Today CT/MRI/SPECT. XD3 also facilitates time saving The Philips IntelliSpace Portal is an excellent measurements; and the Symbia T range, a family of Lilly has around 2500 staff in the UK working across RECIST and volumetric measurements through example of how advanced imaging solutions can SPECT/CT systems offering diagnostic CT three sites; a sales and marketing operation in specialized tools, including automatic CT lesion. In deliver greater collaboration and integration. Now performance with multi-slice technology. For PET Basingstoke, a R&D base in Surrey and a bio-tech 2010, Mirada introduced a powerful range of with access to molecular imaging applications, the investigations, the Biograph mCT system, offers manufacturing facility in Liverpool. www.lilly.co.uk software tools built specifically for Radiation Philips IntelliSpace Portal enables clinicians to upto 128-slice CT technology, combined with PET Stand No.15 Oncology Imaging Systems Ltd are a Oncology. These tools incorporate Mirada’s proven process, analyse, share and review images from all HD algorithms and time-of-flight capabilities to afford company specialising in advanced devices for the fusion technology to support dose warping and molecular imaging modalities including SPECT, unparalleled image quality. For image handling and medical industry including Radiotherapy, CT, PET & summation, atlas based auto-contouring, SPECT/CT, PET-CT and PET/MR anytime, anyplace, processing, a thin client solution meets the needs of MRI, Mammography and Diagnostic Radiology. We deformable fusion of multi-sequence MRI, PET and anywhere. either the SPECT or PET user. In addition PETNET provide solutions, training, advice, products and SPECT, and single click contour warping for rapid Solutions, part of Siemens Molecular Imaging supply customer service to those involved in our business. adaptive re-planning. In addition, powerful imaging And, surprisingly compact given its capabilities, at MetaTrace FDG Fludeoxyglucose [18F] and other At this congress we will be presenting our semi solutions have been recently introduced by Mirada the heart of BrightView XCT is the unique integration [18F] PET tracers to the UK from their 2 cyclotron automatic isotope dispensing unit which has been to support better collaborative working, in particular of BrightView with advanced Philips flat-panel X-ray facilities in Mount Vernon and Nottingham. specifically designed to reduce radiation exposure to in the context of a rich web-based viewer for technology. Substantial clinical advantages include For further technical information please contact: technicians. Contact: Steve Imber Email: referring physicians and a robust solution for co-planar SPECT and CT, flexible CT breathing Siemens Healthcare, [email protected] Telephone number: presentation of images at multidisciplinary meetings. protocols optimised for localisation and attenuation Sir William Siemens Square, Frimley, 01825 840633 Website: www.oncologyimaging.com Visit our website www.mirada-medical.com correction, and high resolution at low CT dose Camberley, Surrey, GU16 8QD levels. Contact us on 01483 298543 or visit Tel: 01276 696439 Fax: 01276 696466 www.philips.com/imaging2.0

41ST ANNUAL MEETING 2 9 21ST-24TH APRIL 2013 Exhibiting companies

Stand No. 3a Medrad® Intego TM PET Infusion System. The Sirtex Medical Europe GmbH is a wholly-owned Intego TM system infuses doses on demand from a subsidiary of Sirtex Medical Limited, a publicly-listed multi-dose vial providing you with greater flexibility, company on the Australian Securities Exchange enhanced workflow, added protection and more engaged in the field of liver-directed therapies for accurate, repeatable patient specific dosing. oncology. Our innovative technology, SIR-Spheres® Our comprehensive solutions and focus on value are microspheres, was approved in 2002 for use in the designed to simplify workflow and improve treatment of unresectable liver tumours within the operational outcomes. Please come to the Bayer European Union under a CE Mark and for the stand to see the Medrad® Intego TM and hear how treatment of colorectal cancer liver metastases in the system will help you in your busy department. combination with FUDR intra-arterial chemotherapy Contact the Customer Service team on by the US Food & Drug Administration. SIR- Tel: 01635 563999 Spheres microspheres are presently used to treat a variety of unresectable liver metastases as well as in hepatocellular carcinoma atover 100 institutions throughout Europe. For more information, please contact Trish O’Neill (National Sales Manager UK & Ireland) on [email protected] 07595154868. ®SIR-Spheres is a Registered Trademark of Sirtex SIR-Spheres Pty Ltd

Stand No. 7 Southern Scientific i s based in Henfield, West Sussex, and has been serving the medical and nuclear market for 25 years. Our customers include hospitals, nuclear power, processing and research sites, industry and the Ministry of Defence. We supply a wide range of Radiation Protection equipment including our Radhound range of Contamination monitors, alongside Scintillation, Contamination and GM probes to suit all applications, Southern Scientific also supplies a wide range of Capintec products, as well as effective decontamination agents and Amici Lung Ventilation equipment. Our talented team of sales, service and applications specialists offer comprehensive product support. Southern Scientific Ltd. is an ISO- 9001/2008 and ISO-13485 company, and all our products are CE marked. Please visit our stand to find out more about our range of products and services.

Stand No. 3b Bayer HealthCare 's Radiology & Interventional. In our organisation, you will find a single source for radiology, interventional, and equipment support services - a trusted leader in patient care and practice solutions. Meet your goals with a comprehensive portfolio of products including the

41ST ANNUAL MEETING 3 0 21ST-24TH APRIL 2013 BNMS membership application form

Application for Full Membership Associate Membership (please tick) Specialty: (For our database please tick ONE category)

Surname: Forename Title Clinician Radiographer Technologist

Hospital/Institute Medical Physicist Radiologist Veterinary Surgeon

Work address Nuclear Physician Radiopharmacist

Nurse Radiotherapist

Postcode Two sponsoring members: for individuals applying for full membership

Tel: Fax: Member’s name

Email: (print carefully) Signature

Home Address Member’s name

Signature

Postcode Your signature

Please send all correspondence to my WORK / HOME address (delete as appropriate) Are you happy for us to include your details in our on-line Members Directory? Yes No

Position/Qualifications: Are you happy for us to forward your details to third parties (e.g. manufacturers)? Yes No

Duration and extent of nuclear medicine responsibilities Note: If you do not answer the above questions we will assume a ‘Yes’ response to both.

41ST ANNUAL MEETING 3 1 21ST-24TH APRIL 2013 Methods of payment

Annual Membership UK Overseas Applications must be accompanied by cheque, bank transfer, money order or credit card details. Alternatively the Society operates a monthly direct debit system. Please request a form from staff Full Member £132.00 £172.00 on the Registration Desk. Payments must be made in sterling drawn on a UK bank made payable to British Nuclear Medicine Society and should be sent with this form to: Full Member – reduced rate £108.00 £122.00 British Nuclear Medicine Society Associate Rate £ 60.00 £ 87.00 Regent House, 291 Kirkdale, London SE26 4QD

The reduced rate is available according to grade of employment as follows: Credit card payments (a) Medical staff, etc. – not holding a consultant or equivalent post (b) Clinical scientist – below NHS B17 or equivalent I authorise you to debit my VISA/Mastercard/American Express/Switch account with the amount (c) Academic staff – below Senior Lecturer or equivalent research staff grade of: (d) Pharmacist – below NHS grade F or equivalent (e) Technologists/Radiographers/Nurses – any grade £

The reduced rate for categories (a) to (d) should be claimed by submitting a signed declaration Card number upon application to join the Society.. Expiry date Issue no. I enclose payment of £ (UK member) Security code (last 3 digits on reverse of card) or £ (Overseas member) Signature Date

41ST ANNUAL MEETING 3 2 21ST-24TH APRIL 2013

Produced by The Design Studio Ref: 4293 March 2013